[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2359
1. Chandrasoma P: The price of doubt is esophageal adenocarcinoma. Ann Surg; 2008 Mar;247(3):558-9; author reply 559-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The price of doubt is esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg. 2007 Jul;246(1):22-3 [17592285.001]
  • (PMID = 18376213.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


2. Wani S, Choi W, Sharma P: Low-grade dysplasia in Barrett's esophagus - an innocent bystander? Pro. Endoscopy; 2007 Jul;39(7):643-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade dysplasia in Barrett's esophagus - an innocent bystander? Pro.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Precancerous Conditions / classification

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2007 Jul;39(7):647-9 [17611921.001]
  • (PMID = 17611920.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Germany
  •  go-up   go-down


3. Wolfsen HC: Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. J Clin Gastroenterol; 2005 Mar;39(3):189-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
  • BACKGROUND: Barrett's esophagus is thought to be the result of long-standing gastroesophageal reflux disease and is known to be the most important risk factor for the development of esophageal adenocarcinoma.
  • The natural history of Barrett's esophagus is not well known, but the annual incidence of invasive adenocarcinoma is estimated to be 0.5% (reported range, 0.2%-2.0%).
  • This represents an increased risk for esophageal cancer of 30 to 60 times higher than normal subjects.
  • As for colorectal cancer, malignant degeneration is Barrett's esophagus is thought to occur through a continuum of histologic stages: metaplasia, dysplasia and neoplasia.
  • CONCLUSIONS: Previously, Barrett's high-grade dysplasia patients were routinely referred for esophageal resection surgery based upon the assumption of inevitable progression to cancer, the high rate of undiagnosed synchronous cancers, and few treatment alternatives.
  • [MeSH-major] Barrett Esophagus / drug therapy. Barrett Esophagus / pathology. Photochemotherapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718860.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether; FU21S769PF / temoporfin
  • [Number-of-references] 166
  •  go-up   go-down


Advertisement
4. Szentpáli K, Széll M, Paszt A, Wolfárd A, Dobozy A, Németh I, Tiszlavicz L, Iván L, Boros M: Simultaneous adeno- and squamous cell carcinoma with different phenotypic profiles in a rat model of chronic gastroesophageal reflux. Dis Esophagus; 2007;20(4):305-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was to investigate the incidence of duodeno-gastroesophageal reflux-induced malignant transformation in a series of duodeno-esophageal anastomosis operations in rats.
  • This surgical method provides a model for reflux-induced esophageal pathologies, without carcinogen administration.
  • Thirty weeks of duodeno-gastroesophageal reflux disease significantly increased the risk of the development of Barrett's esophagus, and reflux-induced esophageal adenocarcinoma formation was evident in four animals.
  • In one of these particular cases, a superficial squamous cell cancer was noted in close vicinity to the adenocarcinoma formation.
  • The specialized intestinal metaplasia and mucinous adenocarcinoma cells exhibited exclusively diffuse cox-2 positivity (90% of all glandular cells) and weak focal c-erbB2 (5%) staining, without cyclin D1 expression or p53 protein accumulation.
  • The most dramatic changes were observed in the level of expression of cyclin D1 (a 9.08-fold expression as compared with the non-treated esophagus samples), while the p53 and cox-2 gene expressions were increased by 1.61 and 2.45-fold, respectively, relative to the non-treated samples.


5. Kim JH, Rhee PL, Lee JH, Lee H, Choi YS, Son HJ, Kim JJ, Rhee JC: Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol; 2007 Jun;22(6):908-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk factors of Barrett's esophagus in Korea.
  • BACKGROUND AND AIM: Barrett's esophagus (BE) is diagnosed when specialized intestinal metaplasia (SIM) is detected histologically in endoscopically suspected columnar-lined esophagus (CLE).
  • It is a premalignant condition and plays a pivotal role in the development of esophageal adenocarcinoma.
  • RESULTS: Barrett's esophagus was present in 151 patients (0.22%) with a mean age of 53.8 +/- 10.9 years.
  • CONCLUSIONS: Barrett's esophagus remains less common in Korea than in Western countries.
  • [MeSH-major] Barrett Esophagus / epidemiology. Barrett Esophagus / etiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565647.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


6. Abdel-Latif MM, Kelleher D, Reynolds JV: Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res; 2009 May 1;153(1):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target.
  • Esophageal adenocarcinoma is increasing in incidence and arises in a background of reflux induced inflammation, metaplasia, and dysplasia.
  • Because a role for NF-kappaB has been implicated in the pathogenesis of esophageal cancer, this transcription factor has been the focus of the current research of this devastating disease.
  • Research efforts to improve the effect of chemotherapy have led to an improvement in patient survival but there is still a need for improvement, and NF-kappaB is a potential target for cancer drug development.
  • In this review, we have attempted to highlight the possible role of NF-kappaB in esophageal adenocarcinoma and discuss the anticancer strategy with NF-kappaB as a promising molecular target in esophageal cancer therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. NF-kappa B / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533190.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / NF-kappa B
  • [Number-of-references] 58
  •  go-up   go-down


7. Liu G, Zhou W, Yeap BY, Su L, Wain JC, Poneros JM, Nishioka NS, Lynch TJ, Christiani DC: XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis; 2007 Jun;28(6):1254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
  • DNA damage is important in the pathogenesis of esophageal adenocarcinoma (EA).
  • [MeSH-major] Adenocarcinoma / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Xeroderma Pigmentosum Group D Protein / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264068.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA109193; United States / NCI NIH HHS / CA / CA110822; United States / NCI NIH HHS / CA / CA74386; United States / NCI NIH HHS / CA / ES/CA06409
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


8. Yong TY, Klebe S, Li JY: Acute critical leg ischemia: an uncommon initial manifestation of esophageal adenocarcinoma. J Palliat Med; 2009 Sep;12(9):841-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute critical leg ischemia: an uncommon initial manifestation of esophageal adenocarcinoma.
  • This report describes a patient who presented with acute critical right leg ischemia leading to the diagnosis of esophageal adenocarcinoma with widespread metastases.
  • However, he died 3 weeks after presentation due to progressive cancer.
  • [MeSH-major] Esophageal Neoplasms / complications. Ischemia / etiology. Leg / blood supply
  • [MeSH-minor] Acute Disease. Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Disease Progression. Fatal Outcome. Humans. Male. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719377.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Selaru FM, Wang S, Yin J, Schulmann K, Xu Y, Mori Y, Olaru AV, Sato F, Hamilton JP, Abraham JM, Schneider P, Greenwald BD, Brabender J, Meltzer SJ: Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinform Biol Insights; 2007;1:127-136
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma.
  • BACKGROUND AND AIMS: Because of the extremely low neoplastic progression rate in Barrett's esophagus, it is difficult to diagnose patients with concomitant adenocarcinoma early in their disease course.
  • If biomarkers existed in normal squamous esophageal epithelium to identify patients with concomitant esophageal adenocarcinoma, potential applications would be far-reaching.
  • The aim of the current study was to identify global gene expression patterns in normal esophageal epithelium capable of revealing simultaneous esophageal adenocarcinoma, even located remotely in the esophagus.
  • METHODS: Tissues comprised normal esophageal epithelia from 9 patients with esophageal adenocarcinoma, 8 patients lacking esophageal adenocarcinoma or Barrett's, and 6 patients with Barrett's esophagus alone. cDNA microarrays were performed, and pattern recognition in each of these subgroups was achieved using shrunken nearest centroid predictors.
  • RESULTS: Our method accurately discriminated normal esophageal epithelia of 8/8 patients without esophageal adenocarcinoma or Barrett's esophagus and of 6/6 patients with Barrett's esophagus alone from normal esophageal epithelia of 9/9 patients with Barrett's esophagus and concomitant esophageal adenocarcinoma.
  • Thus, based on their corresponding normal esophageal epithelia alone, our method accurately diagnosed patients who had concomitant esophageal adenocarcinoma.
  • CONCLUSIONS: These global gene expression patterns, along with individual genes culled from them, represent potential biomarkers for the early diagnosis of esophageal adenocarcinoma from normal esophageal epithelia.
  • Genes discovered in normal esophagus that are differentially expressed in patients with vs. without esophageal adenocarcinoma merit further pursuit in molecular genetic, functional, and therapeutic interventional studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425214.001).
  • [Journal-full-title] Bioinformatics and biology insights
  • [ISO-abbreviation] Bioinform Biol Insights
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA001808; United States / NCI NIH HHS / CA / CA001808-05; United States / NCI NIH HHS / CA / R01 CA095323; United States / NCI NIH HHS / CA / CA095323-13; United States / NCI NIH HHS / CA / R21 CA106763; United States / NCI NIH HHS / CA / CA106763-02; United States / NIDDK NIH HHS / DK / T32 DK067872; United States / NCI NIH HHS / CA / U01 CA085069; United States / NCI NIH HHS / CA / CA085069-07
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


10. Shimpi RA, George J, Jowell P, Gress FG: Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointest Endosc; 2007 Sep;66(3):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of esophageal cancer by EUS: staging accuracy revisited.
  • BACKGROUND: EUS plays an important role in the preoperative staging of esophageal cancer.
  • PATIENTS AND INTERVENTIONS: A total of 42 patients with esophageal cancer undergoing preoperative EUS staging without neoadjuvant chemoradiotherapy between December 1999 and December 2004 were evaluated.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Squamous Cell / pathology. Endosonography. Esophageal Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cohort Studies. Esophagectomy. Esophagus / pathology. Female. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2008 Apr;67(4):774; author reply 774 [18374031.001]
  • (PMID = 17725937.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Watari J, Sakurai J, Morita T, Yamazaki T, Okugawa T, Toyoshima F, Tanaka J, Tomita T, Kim Y, Oshima T, Hori K, Moriichi K, Tanabe H, Fujiya M, Kohgo Y, Das KM, Matsumoto T, Miwa H: A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations. Gastrointest Endosc; 2010 Dec;72(6):1303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Barrett Esophagus / surgery. Epigenesis, Genetic. Esophageal Neoplasms / genetics. Esophageal Neoplasms / surgery. Esophagoscopy. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Antibodies / analysis. DNA Methylation / genetics. Electrocoagulation. Esophagus / pathology. Esophagus / surgery. Genetic Loci / genetics. Humans. Lymphatic Metastasis / pathology. Male. Microsatellite Instability. Middle Aged. Neoplasm Invasiveness. Phenotype. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20650453.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APC protein, human; 0 / Adenomatous Polyposis Coli Protein; 0 / Antibodies; 0 / DAS-1 protein, human
  •  go-up   go-down


12. Lombard C: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2006 Jul;49(1):97-8; author reply 98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies of the cardiac mucosa and Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Aged. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Gastric Mucosa / pathology. Humans. Male. Metaplasia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Histopathology. 2005 Apr;46(4):361-73 [15810947.001]
  • (PMID = 16842257.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


13. Ku GY, Ilson DH: Role of neoadjuvant therapy for esophageal adenocarcinoma. Surg Oncol Clin N Am; 2009 Jul;18(3):533-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of neoadjuvant therapy for esophageal adenocarcinoma.
  • This article examines the role of neoadjuvant therapy in the treatment of locally advanced esophageal adenocarcinoma.
  • Primary chemoradiotherapy is the accepted standard of care for medically inoperable patients, whereas adjuvant chemoradiotherapy may be considered for patients who undergo primary resection of lower esophageal/gastroesophageal junction tumors.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Neoadjuvant Therapy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500742.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 60
  •  go-up   go-down


14. Wood RK, Yang YX: Barrett's esophagus in 2008: an update. Keio J Med; 2008 Sep;57(3):132-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus in 2008: an update.
  • With the rising incidence and overall poor prognosis of esophageal adenocarcinoma (EA) there is great interest in furthering our understanding of Barrett's esophagus, the precursor lesion for most cases of EA.
  • Several risk factors for development of Barrett's have been identified including gastro-esophageal reflux disease (GERD), central obesity, H. pylori eradication, and male gender.
  • The precise incidence of progression from Barrett's to esophageal adenocarcinoma is not known, but it probably is less than 0.5% per year, and our ability to predict who is at highest risk for progression remains poor.
  • The degree of dysplasia is currently used as a marker for risk of progression to cancer though there is increasing evidence that biomarkers and level of genetic instability may provide better predictive measures.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Barrett Esophagus / diagnosis. Barrett Esophagus / therapy. Helicobacter Infections / complications
  • [MeSH-minor] Biomarkers, Tumor. Cyclooxygenase Inhibitors / pharmacology. Disease Progression. Esophageal Neoplasms / complications. Esophageal Neoplasms / etiology. Esophagus / pathology. Female. Gastroenterology / methods. Gastroenterology / trends. Humans. Male. Obesity / complications. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854665.001).
  • [ISSN] 1880-1293
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 40
  •  go-up   go-down


15. Espinel J, Pinedo E, Rascarachi G: Endoscopic mucosal resection with a multiband ligator for the treatment of Barrett s high-grade dysplasia and early gastric cancer. Rev Esp Enferm Dig; 2009 Jun;101(6):403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection with a multiband ligator for the treatment of Barrett s high-grade dysplasia and early gastric cancer.
  • AIM: Due to surgery s high mortality and morbidity, local therapeutic techniques are required for Barrett s high-grade dysplasia (BHGD) and early gastric cancer (EGC).
  • The objective of this study was to evaluate the efficacy and safety of EMR with a ML device in the treatment of Barrett s high-grade dysplasia and early gastric cancer.
  • Barrett s esophagus (BE): one patient with long BE received 3 EMR sessions.
  • The histology of the EMR specimens confirmed a moderately differentiated adenocarcinoma with submucosal infiltration (1 patient) and BHGD (3 patients).
  • Early gastric cancer (EGC): 3 patients had EGC (type IIa) and 1 patient had high-grade dysplasia.
  • The histology of EMR specimens confirmed a mucinous adenocarcinoma with submucosal infiltration (1 patient), EGC (2 patients), and HGD (1 patient).
  • Complications (mild esophageal stenosis, minor bleeding) occurred in 2 patients.
  • [MeSH-major] Barrett Esophagus / surgery. Gastric Mucosa / surgery. Gastroscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630463.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA: Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus; 2008;21(7):575-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction.
  • Thromboembolic event (TEE) is the most common complication and a second cause of mortality in cancer patients.
  • There are no reports on the frequency/impact of TEE in localized gastroesophageal cancer patients.
  • We hypothesized that TEE at baseline and during chemoradiotherapy (CTRT) in gastroesophageal cancer patients would have an impact on overall survival (OS) of these patients.
  • All consecutive patients with gastroesophageal cancer undergoing CTRT from 2001 to 2004 were eligible for this analysis.
  • Our data are the first to document the frequency of TEE in gastroesophageal cancer patients undergoing CTRT, and that TEE is an independent prognosticator of OS.
  • Active research to prevent and treat TEEs is needed to improve survival of patients with localized gastroesophageal cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459989.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH: Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer; 2007 Jun 18;96(12):1823-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality chemoradiation in elderly oesophageal cancer patients.
  • We present a single institution experience with 5-FU, mitomycin-C based chemoradiation for the primary treatment of elderly patients with oesophageal cancer.
  • Twenty-five patients with a median age of 77 years (range 66-88) with a diagnosis of stage II-III squamous cell or adenocarcinoma of the oesophagus were treated at Memorial Sloan Kettering from 1996 to 2001 with two cycles of concurrent 5-FU, mitomycin-C and 50.4 Gy.
  • Eleven patients (44%) are alive and 10 (40%) remain without evidence of recurrent or progressive oesophageal cancer at a median follow-up of 35 months.
  • Similar survival was observed for patients with adenocarcinoma or squamous carcinoma.
  • Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2109-16 [11596027.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2926-32 [12885811.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):45-52 [14701767.001]
  • [Cites] J Chronic Dis. 1987;40(7):705-12 [3110198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29-36 [1704362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):685-8 [2004944.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1225-32 [7525520.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):333-8 [8625111.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1423-7 [9146337.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):725-33 [9250271.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):357-64 [9527058.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):545-53 [9766581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):269-76 [9788404.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):26-31 [9921970.001]
  • [Cites] Ann Thorac Surg. 2005 Feb;79(2):391-7; discussionn 391-7 [15680801.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] World J Gastroenterol. 2006 Feb 28;12(8):1296-9 [16534889.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):455-62 [10653860.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):562-72; discussion 572-3 [10801023.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):414-8 [11235680.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] Dis Esophagus. 2003;16(2):90-3 [12823204.001]
  • (PMID = 17533399.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2359964
  •  go-up   go-down


18. Levine MS: Barrett esophagus: update for radiologists. Abdom Imaging; 2005 Mar-Apr;30(2):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett esophagus: update for radiologists.
  • Barrett esophagus is a well-recognized entity in which there is progressive columnar metaplasia of the lower esophagus due to longstanding gastroesophageal reflux and reflux esophagitis [1].
  • This condition is important because it is associated with an increased risk of developing esophageal adenocarcinoma by a well-established sequence from dysplasia to carcinoma [2].
  • During the past decade, however, an explosion of new data has dramatically affected our understanding of Barrett esophagus.
  • Not only have revised histopathologic criteria been developed for this condition, but it is currently believed that patients with Barrett esophagus should be classified as having "short-segment" or "long-segment" disease based on the extent of columnar metaplasia in the distal esophagus.
  • This distinction has important implications for the risk of developing esophageal adenocarcinoma and subsequent need for endoscopic surveillance.
  • The purpose of this article is to present these new concepts about Barrett esophagus and provide radiologists with a more current framework for diagnosing this condition.
  • [MeSH-major] Barrett Esophagus / radiography
  • [MeSH-minor] Diagnosis, Differential. Esophageal Neoplasms / radiography. Humans. Reproducibility of Results

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602646.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


19. Spechler SJ, Davila R: Endoscopic therapy in Barrett's esophagus: when and how? Surg Oncol Clin N Am; 2009 Jul;18(3):509-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy in Barrett's esophagus: when and how?
  • Endoscopic ablative therapy, and endoscopic mucosal resection (EMR) are the two general types of endoscopic therapies available for the treatment of Barrett's esophagus.
  • In this article, we discuss the use of endoscopic therapies for Barrett's esophagus presenting with no neoplasia, low and high-grade dysplasia, and early adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / surgery. Catheter Ablation / methods. Esophagoscopy / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Adenocarcinoma / surgery. Algorithms. Biopsy. Combined Modality Therapy. Decision Trees. Endosonography. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / etiology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Evidence-Based Practice. Humans. Lymph Node Excision. Neoplasm Staging. Patient Selection. Precancerous Conditions / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / surgery. Proton Pump Inhibitors / therapeutic use. Risk Reduction Behavior. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500740.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Number-of-references] 52
  •  go-up   go-down


20. Shi XY, Bhagwandeen B, Leong AS: p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
  • Barrett esophagus (BE) is an established precursor of esophageal adenocarcinoma (AdenoCa).
  • One hundred and one cases of BE diagnosed by esophageal biopsy and resections were examined morphologically for dysplasia.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665038.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 136601-57-5 / Cyclin D1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


21. Nakajima H, Omura K: [Molecular events associated with Barrett's oesophagus]. Nihon Rinsho; 2005 Aug;63(8):1362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular events associated with Barrett's oesophagus].
  • The development and progression of Barrett's epithelium are accompanied with the acquisition of many molecular changes of the oesophageal mucosa.
  • Gastro-oesophageal reflux and inflammation cause the oxidative stress and free-radical generations, which result in the expression of oxidative-stress-related genes and the induction of DNA damage.
  • The development of Barrett's epithelium follows a metaplasia-dysplasia-adenocarcinoma sequence, characterized by the accumulation of many genetic and epigenetic alterations, which are seen in carcinogenesis.
  • These genetic alterations affecting the cancer hallmarks provide a better understanding of the etiology and pathogenesis of the disease.
  • [MeSH-major] Barrett Esophagus / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Apoptosis / genetics. Cell Transformation, Neoplastic / genetics. Cyclins / physiology. Cyclooxygenase 2. DNA Damage / genetics. Esophageal Neoplasms / genetics. Esophagus / pathology. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Membrane Proteins. Metaplasia / genetics. Mucous Membrane / pathology. Neovascularization, Pathologic / genetics. Prostaglandin-Endoperoxide Synthases. Receptors, Vascular Endothelial Growth Factor. Signal Transduction / genetics. Vascular Endothelial Growth Factor A

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101222.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclins; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 20
  •  go-up   go-down


22. DeMeester SR: EMR for intramucosal adenocarcinoma of the esophagus: does one size fit all? Gastrointest Endosc; 2007 Jan;65(1):14-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EMR for intramucosal adenocarcinoma of the esophagus: does one size fit all?
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Endoscopy, Gastrointestinal. Esophageal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • (PMID = 17185074.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


23. Rajendra S, Kutty KM: Barrett's esophagus surveillance in Asians. J Clin Gastroenterol; 2009 Nov-Dec;43(10):1013-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus surveillance in Asians.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564791.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


24. Madani K, Zhao R, Lim HJ, Casson SM, Casson AG: Obesity is not associated with adverse outcome following surgical resection of oesophageal adenocarcinoma. Eur J Cardiothorac Surg; 2010 Nov;38(5):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity is not associated with adverse outcome following surgical resection of oesophageal adenocarcinoma.
  • OBJECTIVE: To study the impact of obesity on postoperative morbidity and outcome following surgical resection of primary oesophageal adenocarcinoma (EADC).
  • DFS and OS at 5 years were increased for patients who were obese at the time of oesophageal resection (P=0.008).
  • CONCLUSIONS: Obesity is not associated with increased postoperative complication rates or adverse outcome following oesophageal resection, and should therefore not be considered a relative contraindication to the surgical management of EADC.
  • The improved survival of obese patients who underwent oesophageal resection for EADC suggests that further investigation of the association between obesity and oesophageal malignancy is now warranted.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [ErratumIn] Eur J Cardiothorac Surg. 2010 Dec;38(6):820-1
  • (PMID = 20444616.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


25. Zablotska LB, Chak A, Das A, Neugut AI: Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol; 2005 Feb 15;161(4):330-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer.
  • Prior studies have demonstrated that adjuvant radiation therapy following mastectomy for breast cancer increases the risk of second primary esophageal cancer after 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be determined.
  • The authors used 1973-2000 data from the population-based Surveillance, Epidemiology, and End Results Program and estimated relative risks of 2.83 (95% confidence interval: 1.35, 5.92) and 2.17 (95% confidence interval: 1.67, 4.02) for squamous cell esophageal cancer at 5-9 and > or =10 years, respectively, following postmastectomy radiation therapy.
  • This increase was mainly due to tumors located in the upper and middle thirds of the esophagus.
  • No significant increase in risk was found for adenocarcinoma following mastectomy or for any type of esophageal cancer following lumpectomy.
  • In summary, postmastectomy radiation therapy moderately increases the risk of squamous cell esophageal cancer starting 5 years after exposure, which persists after 10 years, with no increase in the risk of adenocarcinoma.
  • This finding appears to be a function of the portals used for postmastectomy radiation therapy, which do not expose the lowest third of the esophagus, where adenocarcinomas commonly arise.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Esophageal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neoplasms, Squamous Cell / etiology
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. SEER Program


26. Belova GV, Mel'chenko DS, Reshetova NV, Frank GA, Sokolov VV: [Barrett's esophagus: endoscopic and immunomorphological parallels]. Eksp Klin Gastroenterol; 2010;(10):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus: endoscopic and immunomorphological parallels].
  • Barrett esophagus is the most serious sequela of the gastroesophageal reflux disease being an obligate precancer with a high index of the neoplastic transformation as to an adenocarcinoma esophagus.
  • THE PURPOSE OF THE PAPER: To reveal the extent of the susceptibility to oncogenesis of the Barrett esophagus-patients and to determine high-risk groups.
  • MATERIALS AND METHODS: Our paper has shown the examination results of the 55 Barrett esophagus-patients (29 women and 26 men at the age of 39 to 62 years old), including 40 intestinal metaplasia-patients and 15 patients of the intestinal metaplasia + dysplasia of long clinical course given corresponding correcting cure.
  • In our investigation a DNA-flow cytometry was a method of determining the adenocarcinoma esophagus risk secondary to the Barrett esophagus as well as an index of the proliferation and an index of the aneuploidy were the factors analyzed.
  • THE RESULTS:. 1) As the pathosis histology-progresses from metaplasia to dysplasia and adenocarcinoma esophagus the increase in the aneuploidy rate, the proliferation index, and S-cycling state cells portion is observed;.
  • 3) the increased aneuploidy index in the presence of the intestinal metaplasia free of esophagus dysplasia can serve as an objective factor for neoplastic progression.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434371.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


27. Canto MI: Barrett's esophagus. Gastrointest Endosc Clin N Am; 2005 Jan;15(1):83-92, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • Esophageal cancer staging is a widely accepted indication for endoscopic ultrasonography (EUS).
  • The evaluation of Barrett's esophagus (BE) with EUS is indicated only when there is high-grade dysplasia or a concern for malignancy in an endoscopic lesion.
  • Because the options for the management of BE and early adenocarcinoma are diverse, proper selection of patients by accurate staging with EUS is critical, particularly when nonoperative management is considered.
  • This article discusses the scientific evidence for the use of EUS in BE or early esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Barrett Esophagus / ultrasonography. Endosonography / methods. Esophageal Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555953.001).
  • [ISSN] 1052-5157
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


28. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, Moskaluk CA, El-Rifai W: Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia; 2005 Sep;7(9):854-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic gastroesophageal reflux disease is a known risk factor for Barrett's esophagus (BE), which induces oxidative mucosal damage.
  • Immunohistochemical staining of GPx3 in matching tissue sections (normal, BE, Barrett's dysplasia, and BA) revealed strong immunostaining for GPx3 in normal esophageal and gastric tissues.
  • However, weak to absent GPx3 staining was observed in Barrett's dysplasia and adenocarcinoma samples where the promoter was hypermethylated.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1999 Nov;27(9-10):951-65 [10569628.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Dis Esophagus. 2000;13(1):28-31 [11005328.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:189-200 [11506813.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):55-9 [11781280.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):22-6 [11808965.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41254-8 [12185074.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1688-97 [12721243.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1195-214 [12832285.001]
  • [Cites] Ann Intern Med. 1978 Jul;89(1):122-7 [208444.001]
  • [Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]
  • [Cites] Arch Biochem Biophys. 1987 Aug 1;256(2):677-86 [3619451.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Arch Biochem Biophys. 1991 May 1;286(2):330-6 [1897960.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Sep;9(9):881-5 [9355787.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1463-71 [9843785.001]
  • [Cites] Nutr Cancer. 1998;32(2):64-70 [9919613.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):81-5 [10076569.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Arch Biochem Biophys. 1993 Sep;305(2):541-5 [8373192.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29382-4 [7961915.001]
  • [Cites] Gut. 1995 Aug;37(2):168-73 [7557561.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):552-6; discussion 556-7 [7491999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2557-63 [8637913.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):30-8 [8695238.001]
  • [Cites] Dis Esophagus. 1997 Jan;10(1):29-32; discussion 33 [9079270.001]
  • [Cites] Exp Physiol. 1997 Mar;82(2):291-5 [9129943.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2619-22 [9205067.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • (PMID = 16229808.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.11.1.- / GPX3 protein, human; EC 1.11.1.9 / Glutathione Peroxidase
  • [Other-IDs] NLM/ PMC1501938
  •  go-up   go-down


29. Pace F, Bazzoli F, Fiocca R, Di Mario F, Savarino V, Vigneri S, Vakil N: The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol; 2009 Apr;21(4):394-408
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Gastroesophageal Reflux / diagnosis. Terminology as Topic
  • [MeSH-minor] Adenocarcinoma / complications. Barrett Esophagus / complications. Chest Pain / etiology. Esophageal Neoplasms / complications. Esophageal Stenosis / complications. Evidence-Based Medicine / methods. Humans. Italy. Language. Practice Guidelines as Topic. Syndrome

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262401.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review; Validation Studies
  • [Publication-country] England
  • [Number-of-references] 133
  •  go-up   go-down


30. Thomas T, de Caestecker JS: Surveillance in Barrett's oesophagus. Eur J Gastroenterol Hepatol; 2006 Jun;18(6):585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance in Barrett's oesophagus.
  • Barrett's oesophagus is a premalignant condition with an increasing incidence of adenocarcinoma.
  • The incidence of oesophageal cancer may not be as high as previously supposed, which could influence both surveillance intervals and cost effectiveness.
  • Issues around patient selection have not been satisfactorily resolved; although most patients at risk are elderly and die of other causes, advanced oesophageal cancer is an unpleasant condition and the prevention of the morbidity associated with this by endoscopic therapy of early lesions may be a worthwhile goal.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology. Population Surveillance. Precancerous Conditions / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702845.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  •  go-up   go-down


31. van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT: Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg; 2005 Jan;9(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations.
  • Distant metastases or local invasion are frequently found during the explorative phase of surgery for esophageal cancer.
  • The records of 203 patients with esophageal cancer who were eligible for curative resection were retrospectively reviewed.
  • In patients with esophageal cancer who are suitable for potentially curative surgery, resection was abandoned mainly because of distant metastases encountered during exploration.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / surgery. Esophageal Neoplasms / diagnostic imaging. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):212-9; discussion 219-20 [11465182.001]
  • [Cites] Chest Surg Clin N Am. 2000 Aug;10 (3):471-85 [10967751.001]
  • [Cites] Eur J Radiol. 2002 Jun;42(3):170-80 [12044696.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 May;113(5):836-46; discussion 846-8 [9159617.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):447-52 [8042043.001]
  • [Cites] Dis Esophagus. 2003;16(4):295-300 [14641292.001]
  • [Cites] Scand J Gastroenterol. 1999 Dec;34(12 ):1178-82 [10636063.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3202-10 [10986052.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):381-6 [9165319.001]
  • [Cites] Eur J Surg Oncol. 2002 Nov;28(7):711-5 [12431467.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):521-7 [9716038.001]
  • [Cites] Eur J Surg. 1992 Oct;158(10 ):537-40 [1360825.001]
  • [Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):161-7 [11809546.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):648-54 [11979245.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):309-12 [15028314.001]
  • [Cites] Gut. 1994 Jul;35(7):941-5 [7794305.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):1026-32 [12400740.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):417-24 [9016218.001]
  • [Cites] Eur J Surg. 2000 Nov;166(11):862-5 [11097152.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):452-8 [11866287.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3199-201 [10986051.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):714-9 [11726846.001]
  • [Cites] Ann Thorac Surg. 2002 Mar;73(3):916-20; discussion 920-1 [11899201.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):20-9 [9934727.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10 (9):1100-5 [14597450.001]
  • [Cites] J Surg Oncol. 1993 Dec;54(4):223-5 [8255082.001]
  • [Cites] Ann Thorac Surg. 1994 Sep;58(3):646-53; discussion 653-4 [7944684.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • (PMID = 15623445.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. DeMeester SR: Endoscopic mucosal resection and vagal-sparing esophagectomy for high-grade dysplasia and adenocarcinoma of the esophagus. Semin Thorac Cardiovasc Surg; 2005;17(4):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection and vagal-sparing esophagectomy for high-grade dysplasia and adenocarcinoma of the esophagus.
  • Once a rare tumor, adenocarcinoma of the esophagus is currently the cancer with the fastest rising incidence in America.
  • In addition to the increasing prevalence of the disease, surveillance programs for patients with Barrett's have led to the identification of increasing numbers of patients with high-grade dysplasia or early-stage esophageal adenocarcinomas.
  • Endoscopic mucosal resection allows precise determination of the depth of tumor invasion and facilitates accurate local staging of early esophageal cancers.
  • A vagal-sparing esophagectomy accomplishes the goal of removing the diseased esophagus while minimizing the physiologic impact of an esophagectomy in patients with early-stage esophageal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagoscopy. Esophagus / pathology. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428038.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


33. Cooper SC, Croft S, Day R, Thomson CS, Trudgill NJ: The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev; 2010 May;19(3):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of oesophageal cancer is not affected by a diagnosis of breast cancer.
  • Oesophageal adenocarcinoma (OAC) is less common and develops at a later age in women compared with men.
  • A cohort of women with breast cancer, a tumour commonly treated with oestrogen antagonists, was examined to identify the subsequent risk of developing OAC.
  • Earlier studies have implicated radiotherapy in increasing oesophageal cancer (OC) risk among women with breast cancer.
  • West Midlands Cancer Intelligence Unit data recording cancer diagnosis and treatment information was examined to identify patients with a first malignant primary breast cancer during 1977-2004.
  • Patients were followed until diagnosis of a second primary cancer, death or end of the time period examined.
  • No difference was identified when examined by OC morphology.There was no association between breast cancer and a second primary OC.
  • Radiotherapy that avoids deep irradiation in the treatment of breast cancer, local nodes or recurrence was not associated with an increased risk of developing a second primary OC.
  • [MeSH-major] Breast Neoplasms / complications. Esophageal Neoplasms / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145541.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


34. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT: Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res; 2006 Aug 1;12(15):4598-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
  • ANXA1 has been implicated in early squamous cell carcinogenesis of esophagus and correlates with degree of tumor differentiation.
  • However, the role of ANXA1 in esophageal adenocarcinoma is unclear.
  • Our goal was to evaluate ANXA1 expression and determine its prognostic significance in adenocarcinoma of the esophagus and esophagogastric junction.
  • EXPERIMENTAL DESIGN: This study included 104 consecutive patients with primary resected esophageal and esophagogastric junction adenocarcinomas (11 stage I, 24 stage II, 53 stage III, and 16 stage IV).
  • CONCLUSION: Our results indicate that high ANXA1 expression is frequent in esophageal and esophagogastric junction adenocarcinomas, correlates with more advanced pathologic T stage and the presence of distant metastasis, and is an independent prognostic factor for patient survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A1 / biosynthesis. Esophageal Neoplasms / metabolism. Esophagogastric Junction / metabolism. Esophagogastric Junction / pathology


35. Bosetti C, Gallus S, Garavello W, La Vecchia C: Smoking cessation and the risk of oesophageal cancer: An overview of published studies. Oral Oncol; 2006 Nov;42(10):957-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking cessation and the risk of oesophageal cancer: An overview of published studies.
  • The epidemiologic studies on oesophageal cancer and smoking cessation published before December 2005 were reviewed here.
  • The results from at least 10 cohort and 10 case-control studies indicated that former smokers had a lower risk of squamous-cell or unspecified oesophageal cancer than current smokers.
  • Most investigations showed that the risk of oesophageal cancer remains elevated many years (at least 10) after cessation of smoking, to decline by about 40% only thereafter.
  • A few studies investigated the effect of smoking cessation on adenocarcinoma, and did not report a clear reduction of risk.
  • Data on oesophageal adenocarcinoma are however too limited to provide adequate inference on the relation with time since smoking cessation.
  • In conclusion, cessation of smoking could have an appreciable impact in reducing (squamous-cell) oesophageal cancer, and represents an obvious priority for prevention and public-health purposes.
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Smoking / adverse effects. Smoking Cessation
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Case-Control Studies. Cohort Studies. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919996.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686859
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


36. Soma T, Kaganoi J, Kawabe A, Kondo K, Tsunoda S, Imamura M, Shimada Y: Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer; 2006 Aug 15;119(4):771-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer.
  • Bile acids are known to promote the growth of gastrointestinal cancer.
  • In vitro, esophageal squamous cell carcinoma (ESCC) cells and esophageal adenocarcinoma cells were studied.
  • Our results suggest that bile acids, important constituents of duodenal fluid, stimulate the development of human esophageal cancer by promoting angiogenesis via the COX-2 pathway.
  • [MeSH-major] Chenodeoxycholic Acid / pharmacology. Esophageal Neoplasms / blood supply. Esophageal Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16557574.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 0GEI24LG0J / Chenodeoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


37. van Heijl M, Sprangers MA, de Boer AG, Lagarde SM, Reitsma HB, Busch OR, Tilanus HW, van Lanschot JJ, van Berge Henegouwen MI: Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol; 2010 Jan;17(1):23-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer.
  • BACKGROUND: In patients with esophageal cancer, evidence for prognostic significance of preoperative quality of life (QoL) is limited, while the prognostic significance of postoperative QoL has not been investigated at all.
  • AIM: To determine whether preoperative and postoperative QoL measurements can predict survival independently from clinical and pathological factors, in patients with potentially curable esophageal adenocarcinoma.
  • CONCLUSION: In the present paper the first large consecutive series of potentially curable esophageal cancer patients is presented in whom prospectively collected QoL data before and after potentially curative surgical resection were used to predict survival.
  • Both preoperative (physical symptoms) and postoperative (social functioning, pain, and activity level) QoL subscales are independent predictors of survival in potentially curable patients with esophageal adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Quality of Life

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Dec;87(12):1716-21 [11122191.001]
  • [Cites] Biometrics. 2001 Mar;57(1):114-9 [11252585.001]
  • [Cites] Gut. 2001 Aug;49(2):227-30 [11454799.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1351-7 [12091066.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1367-72 [14598416.001]
  • [Cites] Qual Life Res. 2004 Mar;13(2):311-20 [15085903.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Med Care. 1988 Jul;26(7):724-35 [3393032.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1034-8 [2257209.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1833-8 [1453197.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1005-53 [15939716.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6865-72 [16192578.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Qual Life Res. 2006 Oct;15(8):1297-306 [16830258.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Ann Thorac Surg. 2007 Apr;83(4):1257-64 [17383322.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1361-8 [17582230.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):888-93 [18268490.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1355-63 [18227528.001]
  • [Cites] Endoscopy. 2008 Jun;40(6):464-71 [18543134.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3289-98 [18670823.001]
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):12-3 [19851809.001]
  • (PMID = 19830496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2805800
  •  go-up   go-down


38. Leers JM, DeMeester SR, Chan N, Ayazi S, Oezcelik A, Abate E, Banki F, Lipham JC, Hagen JA, DeMeester TR: Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg; 2009 Sep;138(3):594-602; discussion 601-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.
  • OBJECTIVE: The Siewert classification system differentiates between adenocarcinoma of the gastroesophageal junction and that of the distal esophagus.
  • METHODS: Records of all patients who underwent resection for adenocarcinoma of the distal esophagus or gastroesophageal junction from 1987 to 2007 were retrospectively reviewed.
  • Based on the endoscopic location of the epicenter of the tumor in relation to the gastroesophageal junction, tumors were categorized in 301 patients as being of the distal esophagus and in 208 as being of the gastroesophageal junction.
  • RESULTS: There were no significant differences in age, sex, or body mass index between patients with adenocarcinoma of the distal esophagus or gastroesophageal junction.
  • Patients with adenocarcinoma of the distal esophagus were more likely to have reflux symptoms (75% vs 53%, P < .0001) and peritumoral intestinal metaplasia (73% vs 51%, P < .0001) and be in a surveillance program (54% vs 9%, P = .0005) compared with patients with adenocarcinoma of the gastroesophageal junction.
  • However, the prevalence and location of nodal metastases was similar, and in node-positive patients mediastinal node involvement was present in more than 40% of the patients in each group (distal esophageal adenocarcinoma, 47%; gastroesophageal junction adenocarcinoma, 41%).
  • Survival was similar (5 years: distal esophageal adenocarcinoma, 45%; gastroesophageal junction adenocarcinoma, 38%; P = .14), as was the prevalence and type of recurrence.
  • CONCLUSION: The prevalence and distribution of lymph node metastases in patients with adenocarcinoma of the distal esophagus and gastroesophageal junction were similar, and after esophagectomy, there was no difference in overall survival or recurrence.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / mortality. Esophagogastric Junction / surgery. Neoplasm Recurrence, Local / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698841.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Choueiri NE, Prather CM: Barrett's esophagus: a pre-cancerous condition approach to diagnosis and management. Mo Med; 2009 Sep-Oct;106(5):339-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus: a pre-cancerous condition approach to diagnosis and management.
  • Barrett's esophagus (BE) results from prolonged uncontrolled gastroesophageal reflux (GERD).
  • High grade dysplasia warrants intervention with ablative techniques or surgery due to the extremely high rate of malignant transformation to esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / therapy
  • [MeSH-minor] Aged. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / surgery. Humans. Male. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902713.001).
  • [ISSN] 0026-6620
  • [Journal-full-title] Missouri medicine
  • [ISO-abbreviation] Mo Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


40. Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C: The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus; 2010 Aug;23(6):451-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data.
  • Barrett's esophagus (BE) is the precursor and the biggest risk factor for esophageal adenocarcinoma (EAC), the solid cancer with the fastest rising incidence in the US and western world.
  • The aim of this study was to use a computer simulation disease model of EAC to determine the estimates for BE prevalence that best align with US Surveillance Epidemiology and End Results (SEER) cancer registry data.
  • The model consists of six health states: normal, gastroesophageal reflux disease (GERD), BE, undetected cancer, detected cancer, and death.
  • First, among these million simulations, the 1000 that best reproduced SEER cancer incidence data were selected.
  • Next, of those 1000 best simulations, the 100 with an overall calculated BE to Detected Cancer rates closest to published estimates were selected.
  • Using our model, an estimated prevalence for BE in the general population of 5.6% (5.49-5.70%) accurately predicts incidence rates for EAC reported to the US SEER cancer registry.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Nutr Cancer. 2000;38(2):186-91 [11525596.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gut. 2003 Aug;52(8):1085-9 [12865263.001]
  • [Cites] World J Surg. 2003 Sep;27(9):999-1008; discussion 1006-8 [12917764.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2390-4 [14638338.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jan 1;19(1):95-105 [14687171.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1692-9 [15188164.001]
  • [Cites] Endoscopy. 1988 May;20(3):95-8 [3383810.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Aug 15;22(4):331-42 [16098000.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1373-4; author reply 1374-5 [16618440.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):113-22 [9834337.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2160-6 [17019737.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26 [17142109.001]
  • [Cites] Radiology. 2008 Mar;246(3):763-71 [18309013.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1179-87 [18483340.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] PLoS One. 2010;5(3):e9483 [20208996.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1259-68 [1551533.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):670-80 [8172136.001]
  • [Cites] Ann Med. 1995 Feb;27(1):67-70 [7742002.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1053-7 [7611195.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1448-56 [9136821.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • (PMID = 20353441.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K25 CA133141; United States / NCI NIH HHS / CA / CA107060-05; United States / NIDDK NIH HHS / DK / R13 DK079674; United States / NCI NIH HHS / CA / CA107060; United States / NCI NIH HHS / CA / K07 CA107060-05; United States / NCI NIH HHS / CA / R01 CA140574-01A1; United States / NCI NIH HHS / CA / CA140574-01A1; United States / NCI NIH HHS / CA / R01 CA140574; United States / NCI NIH HHS / CA / K07 CA107060; United States / NIDDK NIH HHS / DK / DK079674-01; United States / NIDDK NIH HHS / DK / R13 DK079674-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS185014; NLM/ PMC2896446
  •  go-up   go-down


41. Altorki NK, Lee PC, Liss Y, Meherally D, Korst RJ, Christos P, Mazumdar M, Port JL: Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg; 2008 Mar;247(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment.
  • OBJECTIVE: There has been an increase in interest in endoscopic therapy (ET) for intramucosal (T1a) or submucosal (T1b) esophageal carcinoma.
  • The objective of the present study was to determine the prevalence of nodal metastases, lymphatic vascular invasion, and multifocal neoplasia in patients with pT1 esophageal carcinoma who underwent esophagectomy without preoperative therapy and assess their potential implication for ET.
  • METHODS: We retrospectively reviewed the records of all patients who underwent esophagectomy without preoperative therapy for pT1 esophageal cancer.
  • A detailed review of all pathology reports was performed to identify relevant pathologic criteria including depth of invasion (T1a or T1b), cell type (adenocarcinoma/squamous), tumor differentiation (poor vs. well/moderate), extent of Barrett esophagus (short segment [SSBE] and long segment [LSBE]), nodal status, lymphovascular invasion (LVI), and the presence of multifocal neoplasia (MFN) (high-grade dysplasia or invasive carcinoma).
  • Sixty patients had adenocarcinoma.
  • Forty-nine patients had adenocarcinoma with associated BE (23 SSBE, 26 LSBE).
  • CONCLUSION: The combined high incidence of MFN, LVI, and occult nodal metastases does not support the use of ET in patients with T1 esophageal cancer regardless of depth of invasion, cell type, differentiation or extent of BE.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy. Esophagoscopy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2010 Jan;251(1):186-7 [19935402.001]
  • (PMID = 18376186.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Mardini HE: Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer? Am J Gastroenterol; 2005 Apr;100(4):978-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer?
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Cell Transformation, Neoplastic / drug effects. Esophageal Neoplasms / prevention & control. Precancerous Conditions / prevention & control. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • (PMID = 15784046.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


43. Wu X, Lu C, Chiang SS, Ajani JA: Pharmacogenetics in esophageal cancer. Semin Oncol; 2005 Dec;32(6 Suppl 9):S87-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics in esophageal cancer.
  • The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics.
  • This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model.
  • This study has enrolled 235 patients with resectable adenocarcinoma or squamous cell carcinoma of the esophagus who had been treated with chemoradiation followed by esophagectomy.
  • The preliminary finding that methylenetetrahydrofolate reductase polymorphisms modify 5-fluorouracil response supports the hypothesis that response or resistance to therapy in esophageal cancer patients may be modulated by genetic variants involved in the metabolism or mechanism of chemotherapy drug action.
  • Our ongoing esophageal cancer research aims to determine individual pharmacogenetic profiles to identify patients most likely to have chemotherapeutic benefit and patients with the highest risk of suffering genotoxic side effects.
  • This emergent area of biomedicine could lead to substantially improved clinical outcomes for patients with adenocarcinoma or squamous cell carcinoma of the esophagus.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399440.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA111922-02; United States / NCI NIH HHS / CA / R01 CA111922; United States / NCI NIH HHS / CA / R01 CA111922-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Dietz J, Chaves-E-Silva S, Meurer L, Sekine S, de Souza AR, Meine GC: Short segment Barrett's esophagus and distal gastric intestinal metaplasia. Arq Gastroenterol; 2006 Apr-Jun;43(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short segment Barrett's esophagus and distal gastric intestinal metaplasia.
  • BACKGROUND: Short segment Barrett's esophagus is defined by the presence of <3 cm of columnar-appearing mucosa in the distal esophagus with intestinal metaplasia on histophatological examination.
  • Barrett's esophagus is a risk factor to develop adenocarcinoma of the esophagus.
  • While Barrett's esophagus develops as a result of chronic gastroesophageal reflux disease, intestinal metaplasia in the gastric cardia is a consequence of chronic Helicobacter pylori infection and is associated with distal gastric intestinal metaplasia.
  • It can be difficult to determine whether short-segment columnar epithelium with intestinal metaplasia are lining the esophagus (a condition called short segment Barrett's esophagus) or the proximal stomach (a condition called intestinal metaplasia of the gastric cardia).
  • AIMS: To study the association of short segment Barrett's esophagus (length <3 cm) with gastric intestinal metaplasia (antrum or body) and infection by H. pylori.
  • PATIENTS AND METHODS: Eight-nine patients with short segment columnar-appearing mucosa in the esophagus, length <3 cm, were studied.
  • RESULTS: Forty-two from 89 (47.2%) patients were diagnosed with esophageal intestinal metaplasia by histopathology.
  • The mean-age was significantly higher in the group with esophageal intestinal metaplasia.
  • Gastric intestinal metaplasia (antrum or body) was diagnosed in 21 from 42 (50.0%) patients in the group with esophageal intestinal metaplasia and 7 from 47 (14.9%) patients in the group with esophageal columnar appearing mucosa but without intestinal metaplasia.
  • CONCLUSION: Intestinal metaplasia is a frequent finding in patients with <3 cm of columnar-appearing mucosa in the distal esophagus.
  • In the present study, short segment intestinal metaplasia in the esophagus is associated with distal gastric intestinal metaplasia.
  • [MeSH-major] Barrett Esophagus / pathology. Gastroesophageal Reflux / pathology. Helicobacter Infections / pathology. Intestines / pathology. Stomach / pathology


45. Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Zuccaro G, Vargo JJ, Dumot JA, Carroll MA: A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity. Am J Clin Oncol; 2007 Apr;30(2):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
  • OBJECTIVES: This is a report of mature results from a phase II trial of an accelerated multimodality treatment program for locoregionally advanced cancer of the esophagus and gastroesophageal junction with a focus on the impact of clinical heterogeneity on outcomes.
  • METHODS: Eligibility required a diagnosis of esophageal or gastroesophageal junction cancer and an esophageal ultrasound stage of at least T3, N1, or M1A.
  • RESULTS: From October 1999 through March 2003, 93 patients were enrolled; 96% were white, 86% male, and 83% had adenocarcinoma.
  • Freedom from recurrence and distant control were significantly better in patients with 1) earlier pretreatment clinical stage, 2) earlier postinduction pathologic stage, 3) squamous cell cancer, and 4) a pathologic response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction / pathology
  • [MeSH-minor] Adenocarcinoma. Adult. Aged. Carcinoma, Squamous Cell. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414467.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Goldman A, Condon A, Adler E, Minnella M, Bernstein C, Bernstein H, Dvorak K: Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells. Dis Esophagus; 2010 Feb;23(2):83-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells.
  • Barrett's esophagus (BE) is a premalignant condition associated with the development of esophageal adenocarcinoma (EAC).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. TAUROCHOLIC ACID .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549210.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA23074; United States / NIEHS NIH HHS / ES / ES06694; United States / NCI NIH HHS / CA / IP50 CA95060
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Bile Acids and Salts; 0 / Free Radical Scavengers; 0 / Protective Agents; 0 / Reactive Oxygen Species; 0 / Sulfhydryl Compounds; 005990WHZZ / Deoxycholic Acid; 360-65-6 / Glycodeoxycholic Acid; 5E090O0G3Z / Taurocholic Acid; 63231-63-0 / RNA; 640-79-9 / Glycochenodeoxycholic Acid; 64480-66-6 / glycoursodeoxycholic acid; 724L30Y2QR / Ursodeoxycholic Acid; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.15.1.1 / Superoxide Dismutase; G59NX3I3RT / Glycocholic Acid; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


47. Saleh W, Duranceau A, Martin J, Noiseux N, Poirier C, Ferraro P: Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. J Thorac Cardiovasc Surg; 2010 Jan;139(1):217-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Lung Transplantation


48. Reddymasu SC, Sharma P: Advances in endoscopic imaging of the esophagus. Gastroenterol Clin North Am; 2008 Dec;37(4):763-74, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in endoscopic imaging of the esophagus.
  • The introduction of flexible fiberoptic endoscopy in the 1960s was a major step forward in the diagnosis and management of various esophageal disorders.
  • Magnification and high-resolution endoscopy, chromoendoscopy, narrow-band imaging, autofluorescence imaging, and confocal laser endomicroscopy are some of the recent advances that have shown promise in the diagnosis of squamous cell carcinoma, gastroesophageal reflux disease, Barrett's esophagus, and adenocarcinoma of the esophagus.
  • The purpose of this review is to summarize the recent advances in endoscopic imaging of the esophagus and their practical application for the gastroenterologist.
  • [MeSH-major] Endoscopy / methods. Esophagus / pathology
  • [MeSH-minor] Esophageal Diseases / diagnosis. Humans

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028316.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


49. Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen E, Haider M, Darling G: Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer; 2010 Sep 1;116(17):4023-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
  • BACKGROUND: Esophagectomy for locally advanced esophageal cancer (LAEC) is associated with limited survival.
  • METHODS: Patients with LAEC of the thoracic esophagus or gastroesophageal junction underwent chemotherapy with preoperative irinotecan (65 mg/m(2)) plus cisplatin (30 mg/m(2)) on Weeks 1, 2, 4, 5, 7, and 8 with concurrent conformal radiotherapy (40 grays [Gy]/20 fractions during Weeks 4-7) and external beam boost (10 Gy/5 fractions at Week 8).
  • Nineteen patients had American Joint Committee on Cancer stage II, 22 had stage III, and 11 had stage IVA disease.
  • Grade 3 to 4 toxicity (graded according to the National Cancer Institute Common Toxicity Criteria 2.0) during induction included neutropenia (36%), febrile neutropenia (8%), diarrhea (10%), and esophagitis (4%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Esophagectomy. Esophagogastric Junction. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2010. (c) 2010 American Cancer Society.
  • (PMID = 20533506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


50. Dunn LJ, Robertson AG, Immanuel A, Griffin SM: Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture. Ann Thorac Surg; 2010 Feb;89(2):604-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture.
  • Barrett's esophagus results from the long-term effects of both acid and bile reflux.
  • Development of Barrett's epithelium in the esophageal remnant has been reported.
  • Here we report the case of a man who was diagnosed with adenocarcinoma in his esophageal remnant on a background of Barrett's change 52 years after undergoing one of the first esophageal resections for benign disease as a child.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophageal Stenosis / surgery. Esophagitis, Peptic / surgery. Postoperative Complications / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20103354.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Pring C, Dexter S: A laparoscopic vagus-preserving Merendino procedure for early esophageal adenocarcinoma. Surg Endosc; 2010 May;24(5):1195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A laparoscopic vagus-preserving Merendino procedure for early esophageal adenocarcinoma.
  • INTRODUCTION: Laparoscopic vagal preserving oesophagectomy is a recognised treatment option for high-grade dysplasia of the oesophagus.
  • A jejunal interposition, as described by Alvin Merendino in 1955, aims to substitute the lower oesophageal sphincter, thereby treating physiological disorders such as reflux oesophagitis.
  • His pathological specimen reported intramucosal carcinoma and high-grade dysplasia within Barrett's oesophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagus / innervation. Laparoscopy / methods. Vagus Nerve
  • [MeSH-minor] Biopsy. Early Diagnosis. Follow-Up Studies. Humans. Male. Middle Aged. Vagotomy / contraindications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):320-5 [16428038.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Sep;89(6):586-8 [18201472.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2007 Spring;19(1):72-8 [17403461.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Surgery. 2000 Mar;127(3):284-90 [10715983.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):624-30 [10982754.001]
  • [Cites] Gut. 2000 Apr;46(4):574-7 [10716690.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1781-7 [10760752.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5 [16192817.001]
  • [Cites] Ann Surg. 1955 Sep;142(3):486-506 [13249345.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):216-22 [7749697.001]
  • [Cites] Endoscopy. 2008 May;40(5):370-9 [18494132.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):60-7 [15584066.001]
  • [Cites] Gut. 2007 Nov;56(11):1625-34 [17938435.001]
  • (PMID = 19997753.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Chait MM: Gastroesophageal reflux disease: Important considerations for the older patients. World J Gastrointest Endosc; 2010 Dec 16;2(12):388-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal disorder seen in the elderly.
  • They have more esophageal and extraesophageal complications that may be potentially life threatening.
  • Esophageal complications include erosive esophagitis, esophageal stricture, Barrett's esophagus and adenocarcinoma of the esophagus.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S5-9 [19262546.001]
  • [Cites] Gut. 1987 Nov;28(11):1484-8 [3428675.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S17-20 [19262541.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] JAMA. 1997 Aug 27;278(8):659-62 [9272898.001]
  • [Cites] J Am Geriatr Soc. 1992 Dec;40(12):1209-11 [1447435.001]
  • [Cites] Gastroenterol Clin North Am. 1990 Sep;19(3):609-16 [2228166.001]
  • [Cites] World J Gastrointest Endosc. 2010 May 16;2(5):147-54 [21160742.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):2128-38 [16848807.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):431-7 [8042041.001]
  • [Cites] N Engl J Med. 1992 Mar 19;326(12):786-92 [1538721.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):672-5 [14991936.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):149-56 [11818914.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8 Suppl):S15-22 [10950101.001]
  • [Cites] Gastroenterology. 2010 Aug;139(2):409-17 [20451523.001]
  • [Cites] Chest. 2009 Nov;136(5 Suppl):e30 [20162786.001]
  • [Cites] J Am Geriatr Soc. 1998 Dec;46(12):1534-7 [9848814.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1430-6 [15307855.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep 15;18(6):595-604 [12969086.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Jun;14(6):651-68 [10848649.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):368-73 [10685737.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Sep;7(9):953-9 [19375520.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26 [17142109.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):660-4 [14988819.001]
  • [Cites] Gut. 2003 Jan;52(1):34-9 [12477756.001]
  • [Cites] Arch Intern Med. 2001 Jan 8;161(1):45-52 [11146697.001]
  • [Cites] Age Ageing. 2000 Mar;29(2):125-30 [10791446.001]
  • [Cites] Ann Intern Med. 2010 Mar 16;152(6):337-45 [20231564.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2009 Jan;19(1):1-22, v [19232277.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1700-7 [18923172.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):351-3 [9517638.001]
  • [Cites] Gastroenterology. 1982 Oct;83(4):889-95 [7106518.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1652-6 [15330897.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):250-8 [12591037.001]
  • [Cites] Semin Gastrointest Dis. 1999 Jul;10(3):93-102 [10435696.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S26-32 [15324379.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1500-11 [11984534.001]
  • [Cites] Gastroenterology. 2010 Jul;139(1):7-13.e3 [20493864.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S10-6 [19262540.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Jun;8(3):202-7 [16764786.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jan;20(1):26-9 [15610442.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct 1;20(7):751-60 [15379835.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1053-7 [7611195.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S21-6 [19262543.001]
  • (PMID = 21191512.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010469
  • [Keywords] NOTNLM ; Elderly / Gastroesophageal reflux disease / Older patient
  •  go-up   go-down


53. Dinjens WN, Koppert LB, Dezentjé DA, Abbou M, van Ballegooijen ES, Sleddens HF, van Dekken H, Tilanus HW, Wijnhoven BP: Identification of a 7.1-mega base pairs minimal deletion at 14q31.1-32.11 in adenocarcinomas of the gastroesophageal junction. Hum Pathol; 2006 May;37(5):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Chromosome Deletion. Chromosomes, Human, Pair 14. Esophagogastric Junction / pathology. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647950.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


54. Sampliner RE: Medical treatment of Barrett's esophagus: can it prevent cancer? Surg Oncol Clin N Am; 2009 Jul;18(3):503-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of Barrett's esophagus: can it prevent cancer?
  • How can medical therapy prevent cancer if anti-reflux surgery cannot prevent the neoplastic progression of Barrett's esophagus?
  • Can anything short of esophagectomy prevent cancer?
  • In the face of the increasing incidence of adenocarcinoma of the esophagus into the twenty-first century, the medical therapy of Barrett's esophagus and its potential role in preventing cancer are explored.
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / drug therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500739.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Proton Pump Inhibitors
  • [Number-of-references] 29
  •  go-up   go-down


55. Bresalier RS: Barrett's Esophagus and esophageal adenocarcinoma. Annu Rev Med; 2009;60:221-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's Esophagus and esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma (EAC) has risen dramatically over the past three decades in western countries.
  • The importance of Barrett's esophagus (BE) derives from its potential to transform to adenocarcinoma.
  • Adenocarcinomas of the esophagus appear to arise from Barrett's mucosa through progressive degrees of dysplasia, but the pathogenesis and natural history of this process are still unclear.
  • The past few years have seen an explosion in new information and the initiation of longitudinal studies to define the risk of adenocarcinoma in BE, the identification of predictive and prognostic markers of cancer risk, sensitive and cost-effective methods of surveillance, and methods of management of dysplasia and early neoplasia including disease prevention.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology


56. DeMeester SR: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol; 2006 Jan;13(1):12-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.
  • BACKGROUND: Over the past 50 years there has been a remarkable change in the epidemiology of esophageal cancer.
  • Previously rare, adenocarcinoma of the esophagus and gastroesophageal junction is now the most common esophageal cancer, and in the United States the incidence is increasing faster than that of any other malignancy.
  • Surveillance in patients with Barrett's esophagus is identifying adenocarcinoma at an earlier, more curable stage in many patients, and at the same time new endoscopic and surgical options are available for the therapy of these localized tumors.
  • METHODS: This article is a review of the epidemiology, diagnosis, staging, and treatment options for esophageal and gastroesophageal junction adenocarcinoma.
  • RESULTS: The epidemiology, prognosis, patterns of lymphatic metastasis, and survival for esophageal and gastroesophageal junction adenocarcinoma suggest that these tumors are similar.
  • CONCLUSIONS: Surveillance programs for Barrett's are identifying patients with early, curable adenocarcinoma of the esophagus or gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery
  • [MeSH-minor] Barrett Esophagus / pathology. Humans. Incidence. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care. Quality of Life. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378161.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 163
  •  go-up   go-down


57. Rosmolen WD, Boer KR, de Leeuw RJ, Gamel CJ, van Berge Henegouwen MI, Bergman JJ, Sprangers MA: Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus. Endoscopy; 2010 Jul;42(7):525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus.
  • BACKGROUND AND STUDY AIMS: Endoscopic treatment of early neoplasia in Barrett's esophagus preserves the esophagus and is minimally invasive compared with surgical treatment.
  • However, the influence of endoscopic therapy on quality of life (QOL) and fear of cancer recurrence is unknown.
  • We explored QOL and fear of cancer recurrence 12 - 60 months after endoscopic and surgical treatment for early Barrett's neoplasia, using a cross-sectional design.
  • Anxiety and fear of recurrence were measured using the Hospital Anxiety and Depression Scale (HADS) and the Worry Of Cancer Scale (WOCS).
  • CONCLUSION: Preservation of the esophagus after endoscopy treatment, which is preferred from a clinical perspective, may induce fear of cancer recurrence.
  • Proper patient education with specific attention to fear of cancer recurrence may therefore be required.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy / psychology. Neoplasm Recurrence, Local / psychology. Quality of Life

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2011 Jan;43(1):30-3 [21234838.001]
  • (PMID = 20539974.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Turcotte S, Duranceau A: Gastroesophageal reflux and cancer. Thorac Surg Clin; 2005 Aug;15(3):341-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroesophageal reflux and cancer.
  • The causal relationship between GERD and esophageal adenocarcinoma, although unclear just a few decades ago, now is established fairly well.
  • The physiologic changes and the biocellular alterations of the damaged esophageal mucosa are documented better.
  • Despite this knowledge, the dramatic increase in the incidence of esophageal cancer cannot be explained.
  • The absolute risk of esophageal adenocarcinoma arising from GERD is low, and, at present, does not justify population-screening programs.
  • Still, with the notion that adenocarcinoma of the esophagus is an aggressive cancer once documented, important questions still are in need of answers for patients suffering from reflux symptoms.
  • Furthermore, metaplasia of the lower esophagus often is not readily recognizable at endoscopy, and only biopsies can document abnormal histology.
  • A severe and prolonged history of reflux always should orient to the possibility of a reflux-related columnar-lined esophagus.
  • Once documented, Barrett's esophagus needs to be seen as a premalignant condition not necessarily leading to adenocarcinoma formation; despite their increased risk of tumor formation, most patients who have Barrett's esophagus die of other causes.
  • During regular endoscopic follow-up, multilevel circumferential biopsies should document the evolution of the histologic changes in the lower esophagus and at the gastroesophageal junction of these patients.
  • It still is unclear if medicine or surgery provides the best quality of life and the best protection against the development of dysplasia and the possible progression toward adenocarcinoma formation when intestinal metaplasia is present in the esophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Gastroesophageal Reflux / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104125.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


59. Vakoc BJ, Shishko M, Yun SH, Oh WY, Suter MJ, Desjardins AE, Evans JA, Nishioka NS, Tearney GJ, Bouma BE: Comprehensive esophageal microscopy by using optical frequency-domain imaging (with video). Gastrointest Endosc; 2007 May;65(6):898-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive esophageal microscopy by using optical frequency-domain imaging (with video).
  • BACKGROUND: Optical coherence tomography (OCT) has been used for high-resolution endoscopic imaging and diagnosis of specialized intestinal metaplasia, dysplasia, and intramucosal carcinoma of the esophagus.
  • However, the relatively slow image-acquisition rate of the present OCT systems inhibits wide-field imaging and limits the clinical utility of OCT for diagnostic imaging in patients with Barrett's esophagus.
  • OBJECTIVE: This study describes a new optical imaging technology, optical frequency-domain imaging (OFDI), derived from OCT, that enables comprehensive imaging of large esophageal segments with microscopic resolution.
  • The system was used in combination with a balloon-centering catheter to comprehensively image the distal esophagus in swine.
  • The 3-dimensional data sets were used to create cross-sectional microscopic images, as well as vascular maps of the esophagus.
  • CONCLUSIONS: Comprehensive microscopic imaging of the distal esophagus in vivo by using OFDI is feasible.
  • The unique capabilities of this technology for obtaining detailed information of tissue microstructure over large mucosal areas may open up new possibilities for improving the management of patients with Barrett's esophagus.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):537-46 [15812406.001]
  • [Cites] Gastrointest Endosc. 2005 Jun;61(7):879-90 [15933695.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):825-31 [16301020.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):38-43 [16431303.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):467-74 [10744824.001]
  • [Cites] Circulation. 2005 Mar 29;111(12):1551-5 [15781733.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):88-95 [11756926.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):84-8 [11756925.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):474-9 [10744825.001]
  • [Cites] Nat Med. 2006 Dec;12(12):1429-33 [17115049.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):196-202 [12872085.001]
  • [Cites] Opt Lett. 2003 Nov 1;28(21):2067-9 [14587817.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • (PMID = 17383652.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R01 RR019768-03; United States / NCI NIH HHS / CA / R01 CA103769-03; United States / NCRR NIH HHS / RR / RR019768-03; United States / NCI NIH HHS / CA / CA103769-03; United States / NCI NIH HHS / CA / R33 CA110130-02; United States / NCI NIH HHS / CA / R33 CA110130; United States / NCI NIH HHS / CA / R01 CA103769; United States / NCRR NIH HHS / RR / R01 RR0119768; United States / NCI NIH HHS / CA / CA110130-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS118155; NLM/ PMC2705339
  •  go-up   go-down


60. Savoy AD, Wolfsen HC, Raimondo M, Woodward TA, Noh K, Pungpapong S, Hemminger LL, Wallace MB: The role of surveillance endoscopy and endosonography after endoscopic ablation of high-grade dysplasia and carcinoma of the esophagus. Dis Esophagus; 2008;21(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surveillance endoscopy and endosonography after endoscopic ablation of high-grade dysplasia and carcinoma of the esophagus.
  • Barrett's esophagus (BE) with high-grade dysplasia (HGD) or early carcinoma treated with surgery or photodynamic therapy (PDT) is at risk of recurrence.
  • Recurrent or residual adenocarcinoma (ACA) was detected in four patients during follow-up.
  • In the fourth patient, CT scan revealed perigastric lymphadenopathy and EUS-FNA (fine needle aspiration) confirmed adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269644.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Bergqvist M, Brattström D, Brodin D, Lindkvist A, Dahlman-Wright K, Dreilich M, Wagenius G, Paulsson-Karlsson Y: Genes associated with telomerase activity levels in esophageal carcinoma cell lines. Dis Esophagus; 2006;19(1):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genes associated with telomerase activity levels in esophageal carcinoma cell lines.
  • Ten human esophageal carcinoma cell lines were investigated using the telomerase activity assay (TRAPeze) Telomerase Detection Kit), followed by further characterization using the GeneChip Human Genome U133A 2.0 Array (Affymetrics Inc., USA), including 14 500 human genes.
  • In conclusion, the present microarray data provide primary validation data indicating possible candidates for prognostic and prediction factors in esophageal cancer in relation to telomerase activity.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364039.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNG2 protein, human; 0 / Cyclin G2; 0 / Cyclins; 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130; 0 / Ribosomal Proteins; 0 / ribosomal protein L3; EC 2.3.- / Acyltransferases; EC 2.3.1.97 / glycylpeptide N-tetradecanoyltransferase; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


62. Falk GW: Risk factors for esophageal cancer development. Surg Oncol Clin N Am; 2009 Jul;18(3):469-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for esophageal cancer development.
  • The incidence of esophageal adenocarcinoma is increasing at a rate greater than that of any other cancer in the Western world today.
  • Barrett's esophagus is a clearly recognized risk factor for the development of esophageal adenocarcinoma, but the overwhelming majority of patients with Barrett's esophagus will never develop esophageal cancer.
  • To date, dysplasia remains the only factor useful for identifying patients at increased risk for the development of esophageal adenocarcinoma in clinical practice.
  • Factors that may protect against the development of adenocarcinoma include infection with Helicobacter pylori, a diet rich in fruits and vegetables, and consumption of aspirin and NSAIDs.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500737.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 125
  •  go-up   go-down


63. Wu G, Bybel B, Brunken R, Lin H, Neumann D: PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma. Clin Nucl Med; 2005 May;30(5):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma.
  • A 67-year-old man with progressive dysphagia was recently diagnosed with a gastroesophageal junction adenocarcinoma.
  • Needle biopsy was performed and confirmed metastatic esophageal adenocarcinoma.
  • A case of skeletal muscle metastases from late-stage (IV) gastroesophageal adenocarcinoma was previously reported.
  • The case supports the previous report that PET is superior in detecting distant metastases for initial staging of esophageal carcinoma over CT.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Muscle Neoplasms / radionuclide imaging. Muscle Neoplasms / secondary. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827406.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Lin L, Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG: Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer; 2006 Apr;45(4):319-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma.
  • Gene amplification is one of the mechanisms to activate oncogenes in many cancers, including esophageal adenocarcinoma (EA).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 3. Esophageal Neoplasms / genetics


65. Takubo K, Aida J, Sawabe M, Arai T, Kato H, Pech O, Arima M: The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract Res Clin Gastroenterol; 2008;22(4):569-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of primary oesophageal adenocarcinoma in Caucasian men has recently been increasing rapidly.
  • Therefore, primary oesophageal adenocarcinoma, columnar-lined oesophagus (CLO) or Barrett's oesophagus and the normal condition of the lower segment of the oesophagus are currently receiving worldwide attention in the medical field.
  • We review definitions of the OGJ, the pattern of the squamocolumnar junction (SCJ), oesophageal cardiac-type glands beneath the squamous epithelium, the normal squamous epithelium, columnar islands in squamous-lined mucosa, squamous islands in CLO and newly reported metaplastic changes in the OGJ zone.
  • [MeSH-minor] Biopsy. Esophageal Sphincter, Upper / cytology. Humans. Stomach / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656817.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


66. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, Saltz LB, Qin J, Landmann R, Leonard GD, Dhall D, Temple L, Guillem JG, Paty PB, Kelsen D, Wong WD, Klimstra DS: Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol; 2008 May;32(5):719-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the current time, neither the World Health Organization nor American Joint Committee on Cancer includes this condition in the histologic classifications, and consequently it is being diagnosed and treated inconsistently.
  • Guided primarily by the World Health Organization/International Association for the Study of Lung Cancer criteria for pulmonary neuroendocrine tumors, we were able to classify 87 high-grade GI tract tumors that initially carried a diagnosis of either poorly differentiated carcinoma with or without any neuroendocrine characteristics, small cell carcinoma, or combined adenocarcinoma-neuroendocrine carcinoma into the following 4 categories.
  • The fourth was poorly differentiated adenocarcinoma (n=17).
  • Further analysis showed that most HGNECs arising in the squamous lined parts (esophagus and anal canal) were small cell type (78%), whereas most involving the glandular mucosa were large cell (53%) or mixed (82%) type; associated adenocarcinomas were more frequent in large cell (61%) or mixed (36%) type than in small cell type (26%); and focal intracytoplasmic mucin was seen only in large cell or mixed type.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / diagnosis. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Tract / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. New York / epidemiology. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360283.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV: Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg; 2010 Jul;97(7):1020-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma.
  • BACKGROUND: Obesity is associated with oesophageal adenocarcinoma, but mechanisms linking fat and carcinogenesis remain poorly understood.
  • METHODS: Seventy-five patients with oesophageal adenocarcinoma underwent anthropometric and radiological assessment of obesity.
  • The human oesophageal adenocarcinoma cell line OE33 was used as the calibrator sample.
  • CONCLUSION: Obesity is associated with upregulated ObR and AdipR2 expression in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Esophageal Neoplasms. Esophagogastric Junction. Obesity, Abdominal / complications. Receptors, Adiponectin / metabolism. Receptors, Leptin / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20632267.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOR1 protein, human; 0 / ADIPOR2 protein, human; 0 / Adipokines; 0 / Receptors, Adiponectin; 0 / Receptors, Leptin
  •  go-up   go-down


68. Wang RH: [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Sep;39(5):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia].
  • Barrett's esophagus is now clearly recognized as a preneoplasic condition.
  • Progression of metaplasia through dysplasia to adenocarcinoma is a widely accepted theory for esophageal carcinogenesis.
  • That high grade dysplasia is frequently found in association with esophageal adenocarcinoma.
  • Long-term endoscopic surveillance of high grade dysplasia in Barrett's esophagus facilitates detection and treatment of esophageal cancers in the early stage.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / therapy. Esophagoscopy
  • [MeSH-minor] Esophageal Neoplasms / diagnosis. Humans. Hyperplasia / pathology. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936731.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


69. Barr H, Kendall C, Bazant-Hegemark F, Moayyedi P, Shetty G, Stone N: Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed; 2006;8(2):88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic screening and surveillance for Barrett's esophagus--clinical implications.
  • There is now a clear causal relationship between symptomatic gastroesophageal reflux and esophageal adenocarcinoma (Lagergren et al, 1999).
  • Screening a high-risk group such as men with gastroesophageal reflux disease (GERD) will result in the detection of more patients with Barrett's esophagus, many of whom are asymptomatic.
  • There are profound challenges with the accurate endoscopic and pathologic detection and categorization of Barrett's metaplasia, dysplasia , and, indeed, cancer.
  • New endoscopic detection methods are being investigated to improve the diagnosis and definition of the premalignant phenotype.
  • [MeSH-major] Barrett Esophagus / pathology. Esophagoscopy
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Humans. Population Surveillance

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gut. 2001 Dec;49(6):761-6 [11709508.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jan;16(1):41-50 [11856077.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):820-3 [11875016.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):274-9 [11943125.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1319-27 [12094844.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Gut. 2002 Sep;51(3):313-4 [12171948.001]
  • [Cites] Gut. 2002 Sep;51(3):314-5 [12171949.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gut. 2002 Nov;51(5):620-1 [12377793.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Gut. 2003 Jan;52(1):18-23 [12477753.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1758-66 [12806608.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):505-14 [14640762.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):112-27 [14653411.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Z Gastroenterol. 2004 Jun;42(6):499-504 [15190444.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gut. 1995 Jul;37(1):7-12 [7672684.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2291-3 [15571569.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2293-5 [15571570.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):561-74 [16185971.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • (PMID = 16926827.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  • [Other-IDs] NLM/ PMC1785170
  •  go-up   go-down


70. Yakoub D, Keun HC, Goldin R, Hanna GB: Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res; 2010 Nov 15;70(22):9129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients.
  • The variable rate of missed cancer in endoscopic biopsies and lack of other biomarkers reduce the effectiveness of surveillance programs in esophageal cancer.
  • Based on the "field cancerization" hypothesis that tumors arise within a transformed field with an altered biochemical phenotype, we sought to test if metabolic profiling could differentiate between histologically normal tissue from individuals with and without esophageal cancer.
  • Thirty-five patients with esophageal adenocarcinoma and 52 age-matched controls participated in the study.
  • Using 1H magic angle spinning-nuclear magnetic resonance spectroscopy of intact tissue, we generated metabolic profiles of tumor tissue, proximal histologically normal mucosa from cancer patients (PHINOM), and proximal histologically normal mucosa from a control group.
  • Using multivariate regression and receiver-operator characteristic analysis, we identified a panel of metabolites discriminating malignant and histologically normal tissues from cancer patients and from that of controls.
  • In particular, the PC/Glu ratio in histologically normal tissue signified the presence of esophageal cancer (n=123; area under the curve, 0.84; P<0.001).
  • In conclusion, our findings support the hypothesis of the presence of metabonomic field effects in esophageal cancer, even in non-Barrett's segments.
  • This indicates that metabolic profiling of tissue can potentially play a role in the surveillance of cancer by reporting on the phenotypic consequences of field cancerization.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Metabolome. Mucous Membrane / metabolism
  • [MeSH-minor] Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Cell Transformation, Neoplastic / metabolism. Diagnosis, Differential. Esophagus / metabolism. Esophagus / pathology. Female. Glutamic Acid / metabolism. Humans. Inosine / metabolism. Inositol / metabolism. Magnetic Resonance Spectroscopy. Male. Middle Aged. Multivariate Analysis. Phosphorylcholine / metabolism. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AACR.
  • (PMID = 20884633.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 107-73-3 / Phosphorylcholine; 3KX376GY7L / Glutamic Acid; 4L6452S749 / Inositol; 5A614L51CT / Inosine
  •  go-up   go-down


71. Richter JE: Short segment Barrett's esophagus: ignorance may be bliss. Am J Gastroenterol; 2006 Jun;101(6):1183-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short segment Barrett's esophagus: ignorance may be bliss.
  • Data suggest the incidence of Barrett's esophagus is increasing, but the vast majority are of the short segment (SS) variety.
  • Whether SSBE has an increased cancer risk is poorly defined, whereas overdiagnosis is common and it is associated with increased insurance costs and perception of cancer risks.
  • [MeSH-major] Barrett Esophagus / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / pathology. Esophagoscopy. Humans. Incidence. Precancerous Conditions / epidemiology. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16771934.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


72. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, South Australian Oesophageal Research Group: MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg; 2010 Jun;97(6):853-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
  • BACKGROUND: The genetic changes that drive metaplastic progression from squamous oesophageal mucosa toward intestinal metaplasia and adenocarcinoma are unclear.
  • The aberrant expression of microRNAs (miRNAs) is involved in the development of cancer.
  • This study examined whether miRNAs play a role in the development of oesophageal adenocarcinoma.
  • METHODS: RNA was extracted from mucosa of normal oesophageal squamous epithelium, normal gastric epithelium, Barrett's oesophagus with intestinal metaplasia and oesophageal adenocarcinoma obtained from 16 individuals.
  • Expression of miR-143, miR-145 and miR-215 was lower in oesophageal adenocarcinoma than in Barrett's oesophagus.
  • MiR-205 levels were lower in gastric epithelium than in both Barrett's oesophagus and adenocarcinoma.
  • CONCLUSION: Expression of miRNA might define disease states in oesophageal epithelium.
  • Dysregulation of specific miRNAs could contribute to metaplastic and neoplastic processes in the oesophageal mucosa.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. MicroRNAs / analysis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20301167.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger
  • [Investigator] Wijnhoven BP; Hussey DJ; Watson DI; Smith CM; Mayne GC; Michael MZ; Astill D; Van der Hoek MB; Tsykin A; Tilanus HW; Wijnhoven BP
  •  go-up   go-down


73. Cai JH, Zhao R, Zhu JW, Jin XL, Wan FJ, Liu K, Ji XP, Zhu YB, Zhu ZG: Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma. J Gastrointest Surg; 2010 Aug;14(8):1248-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.
  • BACKGROUND: The present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II-III colorectal cancer (CRC).
  • In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / metabolism. Cortactin / biosynthesis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2008;55(2):138-42 [18237252.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):956-64 [18268492.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):370-4 [11267876.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):323-35 [12755491.001]
  • [Cites] J Histochem Cytochem. 2007 Sep;55(9):955-62 [17510372.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3433-9 [18846401.001]
  • [Cites] J Pathol. 2009 Mar;217(4):516-23 [18991334.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):231-5 [11227940.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):875-81 [8076486.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):950-5 [18268491.001]
  • [Cites] N Engl J Med. 1978 Aug 31;299(9):448-51 [683276.001]
  • [Cites] J Surg Res. 2008 Jun 1;147(1):99-107 [17655863.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):271-5 [10958511.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):409-14 [10023012.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1424-9 [7226068.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1901-5 [17649792.001]
  • [Cites] Gene. 1995 Jun 14;159(1):83-96 [7607576.001]
  • [Cites] Dis Markers. 2008;25(1):17-26 [18776588.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1420-9 [15007086.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):113-20 [16261345.001]
  • [Cites] Dis Esophagus. 2009;22(5):402-8 [19207554.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1271-6 [19885549.001]
  • [Cites] Dis Colon Rectum. 2001 Dec;44(12):1791-9 [11742164.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):13-25 [15186216.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):629-36 [15464244.001]
  • [Cites] Br J Surg. 1980 Jan;67(1):46-8 [7357243.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2795-803 [16675573.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):69-79 [18575752.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Lett. 2008 Jul 8;265(2):157-66 [18406052.001]
  • [Cites] Nat Med. 2006 Aug;12(8):875-8 [16892025.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):48-53 [12552080.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4953-5 [11326645.001]
  • [Cites] Dis Markers. 2009;26(1):9-18 [19242064.001]
  • [Cites] Cancer Res. 1986 Aug;46(8 Suppl):4244s-4248s [3524805.001]
  • [Cites] APMIS. 2009 Mar;117(3):162-75 [19245589.001]
  • [Cites] Dis Esophagus. 2008;21(5):402-8 [19125793.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5229-34 [1394126.001]
  • [Cites] Exp Cell Res. 2006 May 15;312(9):1658-70 [16527272.001]
  • (PMID = 20532661.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cortactin
  •  go-up   go-down


74. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, vanHam SM, Krishnadath KK: Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol; 2008 Dec;68(6):616-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
  • Immunotherapy for solid cancers, such as oesophageal adenocarcinoma (OAC), is generally hampered by an unfavourable immunological tumour microenvironment.
  • The OAC microenvironment is characterized by a lack of cytokines and factors that normally would enhance anti-cancer responses, such as IFN-gamma and GrB, and by a high expression of several immuno-suppressive factors, such as COX-2, VEGF and IL-8.
  • [MeSH-major] Adenocarcinoma / immunology. Cyclooxygenase 2 / metabolism. Cytokines / metabolism. Esophageal Neoplasms / immunology. Tumor Escape. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055699.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


75. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P: Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol; 2010 Dec;34(12):1868-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Her-2 in carcinomas of the esophagus.
  • Her-2-targeted therapy has recently been shown to be beneficial for patients with advanced gastric cancer.
  • Her-2 protein expression was investigated in 341 esophageal carcinomas [152 squamous cell carcinomas (SCC), 189 adenocarcinomas (AC)], 39 cases of Barrett mucosa, and 11 cases of squamous cell dysplasia.
  • Although Her-2-overexpression in esophageal cancer seems to have no influence on patients' survival, these subtypes of esophageal ACs have to be considered as targets for an anti-Her-2 therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Receptor, ErbB-2 / metabolism


76. Dim DC, Nugent SL, Peng HQ: Ganglioneuroma presenting as a paraesophageal mass lesion diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report. Acta Cytol; 2010 May-Jun;54(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration is a well-established modality in detection and diagnosis of mediastinal lesions.
  • Ganglioneuroma in a surgical specimen is a straightforward diagnosis; however, due to the infrequent occurrence of this entity, diagnosis by fine needle aspiration is more challenging.
  • A 75-year-old man with a history of adenocarcinoma of the lung was noted to have a mediastinal mass on chest computed tomography.
  • Upper endosonography identified a 40x17-mm mass extrinsic to the thoracic esophagus.
  • [MeSH-major] Ganglioneuroma / diagnosis. Mediastinal Neoplasms / pathology. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endosonography. Esophagus / pathology. Humans. Male. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518419.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


77. Metzger R, Drebber U, Baldus SE, Mönig SP, Hölscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann Surg Oncol; 2009 Feb;16(2):447-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus.
  • The aim of this study was to assess the prevalence and prognostic impact of LNI in patients with resected esophageal cancer, comparing adenocarcinoma (AC) and squamous cell carcinoma (SCC).
  • Between 1997 and 2006, 243 consecutive patients with resected esophageal cancer without neoadjuvant therapy (103 SCC, 140 AC) were studied.
  • However the number of infiltrated LN was significantly (p = 0.005) higher in patients with pN1 AC (median = 5) compared with pN1 SCC (median = 3).
  • We conclude that extracapsular LNI is an independent negative prognostic factor which occurs more frequently in esophageal AC than SCC.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagectomy. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037700.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Bird-Lieberman EL, Fitzgerald RC: Early diagnosis of oesophageal cancer. Br J Cancer; 2009 Jul 07;101(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early diagnosis of oesophageal cancer.
  • Squamous cell carcinoma and adenocarcinoma of the oesophagus are cancers that develop from distinct epithelial sub-types; however, they are both related to chronic inflammation of differing aetiologies.
  • It is therefore vital to diagnose oesophageal cancer at an early stage, before the development of symptoms, when treatment can dramatically improve prognosis.
  • [MeSH-major] Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Early Detection of Cancer. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Gastrointest Endosc. 2009 Apr;69(4):777-83 [19136106.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3135-8 [11595706.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2879-82 [12231531.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):868-79 [15476150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):121-30 [9037563.001]
  • [Cites] Dis Esophagus. 1997 Jul;10(3):155-8 [9280071.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):220-31 [9669803.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):671-8 [15855970.001]
  • [Cites] Gut. 2006 Aug;55(8):1078-83 [16469795.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):176-85 [16860064.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):693-700 [17704887.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5 [18559552.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jul;136(1):199-204 [18603076.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1422-8 [18546259.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2008 May;(540):1-224 [18685714.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3278-88 [18726651.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] Gut. 2008 Dec;57(12):1648-53 [18755886.001]
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6444-52 [19030194.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2694-9 [18853967.001]
  • [Cites] Dis Esophagus. 2008;21(5):395-401 [19125792.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):357-61 [19137073.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):70-1 [19065128.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • (PMID = 19513070.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC2713695
  •  go-up   go-down


79. Okoro NI, Wang KK: Changing faces of Barrett's esophagus: implications for adenocarcinoma. Gastroenterology; 2010 Apr;138(4):1620-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing faces of Barrett's esophagus: implications for adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gut. 2009 Feb;58(2):182-8 [18978173.001]
  • (PMID = 20178841.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Rios C PJ, Huam G M, Ríos T PO: [Esophageal cancer in Hospital Rebagliati: experience of esophagus-stomach service 3 C-II]. Rev Gastroenterol Peru; 2007 Oct-Dec;27(4):416-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esophageal cancer in Hospital Rebagliati: experience of esophagus-stomach service 3 C-II].
  • [Transliterated title] Cáncer de esófago en el Hospital Rebagliati: experiencia del servicio esófago estómago 3C-II.
  • OBJECTIVES: Establishing the clinical pathological characteristics of cancer of the esophagus of an insured population in our environment.
  • MATERIAL AND METHODS: In this retrospective study , we studied 28 clinical histories of patients with a diagnosis of esophagus Cancer, who had been surgically treated at the Rebagliati Hospital, Service of Surgery 3C II, Lima-Perú from September 2002 to December 2005.
  • Distribution according to anatomic locations : 10.7% (3/28) were located at the esophagus cervical, 17.9% (5/28) in the upper esophagus chest, 35.7% (10/28) in the middle esophagus chest, 14.3% (4/28) in the lower esophagus chest and the 21.4% (6/28) in the abdominal esophagus.
  • CONCLUSIONS: At our Hospital there seems to be an increase in the frequency of adenocarcinoma of the esophagus, but the type more frecuently is epidermoid.
  • [MeSH-major] Esophageal Neoplasms

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18183284.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


81. Maqani N, Belkhiri A, Moskaluk C, Knuutila S, Dar AA, El-Rifai W: Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res; 2006 Jul;4(7):449-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA amplification at 17q is frequently detected in upper gastrointestinal adenocarcinomas (UGC; stomach and esophagus).
  • Adenocarcinomas of gastroesophageal junction and lower esophagus had the highest frequency of amplification (45%) compared with stomach tumors (27%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 17 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics


82. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A: A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer; 2008 Feb;44(3):465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
  • We examined the association between BMI and EADC, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in a cohort of approximately 500,000 people in the United States (US).
  • We found that compared to people with a BMI of 18.5-25kg/m2, a BMI > or = 35 was associated with significantly increased risk of EADC, HR (95% CI)=2.27 (1.44-3.59) and gastric cardia adenocarcinoma 2.46 (1.60-3.80), but not gastric non-cardia adenocarcinoma 0.84 (0.50-1.42).
  • [MeSH-major] Adenocarcinoma / etiology. Attitude to Health. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):319-23 [3856045.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18221867.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS42480; NLM/ PMC2350215
  •  go-up   go-down


83. Siddiqui AA, Glynn C, Loren D, Kowalski T: Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study. Dis Esophagus; 2009;22(3):216-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study.
  • In patients undergoing chemoradiotherapy for esophageal cancer, the inability to eat may severely impair nutritional status.
  • We conducted a retrospective study to compare the efficacy of the Polyflex self-expanding silicone stent (PS) versus a jejunostomy tube (JT) for maintaining nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer who were scheduled for resectional surgery.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207544.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


84. Avilés A, Reymunde A, Santiago N: Balloon-based electrode for the ablation of non-dysplastic Barrett's esophagus: ablation of intestinal metaplasia (AIM II Trial). Bol Asoc Med P R; 2006 Oct-Dec;98(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balloon-based electrode for the ablation of non-dysplastic Barrett's esophagus: ablation of intestinal metaplasia (AIM II Trial).
  • INTRODUCTION: Barrett's esophagus (BE) is a condition in which an abnormal intestinal-type epithelium called specialized intestinal metaplasia (SIM) replaces the stratified squamous epithelium that normally lines the distal esophagus.
  • This intestinal metaplasia predisposes patients to esophageal adenocarcinoma, the most rapidly rising tumor incidence over the last 30 years, with an annual incidence of 0.5% in patients with BE and a survival rate less than 10% in 5 years.
  • The objective of the study was to assess the safety and efficacy of circumferential endoscopic ablation of Barrett's esophagus using the HALO360 System.
  • METHODS: Patients with non-dysplastic Barrett's esophagus confirmed within the previous year were treated twice per session with a balloon-based, bipolar radiofrequency ablation device with a pre selected energy of 10 J/ cm2 at 260 W for 10 secs, achieving full thickness ablation of epithelium followed by Omeprazole 40 mg PO BID for 1 month and then, daily.
  • [MeSH-major] Barrett Esophagus / surgery. Catheter Ablation / instrumentation. Catheterization / instrumentation
  • [MeSH-minor] Electrodes. Equipment Design. Esophagus / pathology. Esophagus / surgery. Female. Humans. Male. Metaplasia. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19610568.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Puerto Rico
  •  go-up   go-down


85. Finley JC, Reid BJ, Odze RD, Sanchez CA, Galipeau P, Li X, Self SG, Gollahon KA, Blount PL, Rabinovitch PS: Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev; 2006 Aug;15(8):1451-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability in Barrett's esophagus is related to telomere shortening.
  • Barrett's esophagus is a useful model for the study of carcinogenesis, as the metaplastic columnar epithelium that replaces squamous esophageal epithelium is at elevated risk for development of adenocarcinoma.
  • We examined telomere length and chromosomal instability (CIN) in Barrett's esophagus biopsies using fluorescence in situ hybridization.
  • To study CIN, we selected centromere and locus-specific arm probes to chromosomes 17/17p (p53), 11/11q (cyclin D1), and 9/9p (p16 INK4A), loci reported to be involved in early stages of Barrett's esophagus neoplasia.
  • Telomere shortening was observed in Barrett's esophagus epithelium at all histologic grades, whereas CIN was highest in biopsies with dysplastic changes; there was, however, considerable heterogeneity between patients in each variable.
  • We conclude that CIN is related to telomere shortening in Barrett's esophagus but varies by chromosome.
  • Because telomere shortening and CIN are early events in Barrett's esophagus neoplastic progression and are highly variable among patients, it will be important to determine whether they identify a subset of patients that is at risk for more rapid neoplastic evolution.
  • [MeSH-major] Barrett Esophagus / genetics. Chromosomal Instability. Esophageal Neoplasms / genetics. Telomere / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Anaphase / genetics. Chromosomes, Human / genetics. Esophagus / metabolism. Flow Cytometry. Gastroesophageal Reflux / genetics. Gastroesophageal Reflux / pathology. Humans. In Situ Hybridization, Fluorescence / methods. Metaplasia / genetics. Middle Aged

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA91955; United States / NIA NIH HHS / AG / P30AG13280; United States / NCI NIH HHS / CA / T32CA09437
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


86. Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-Kenudson M, Lauwers GY: Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol; 2009 Apr;33(4):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia.
  • Endoscopic mucosal resection (EMR) is being advocated as a diagnostic, staging, and therapeutic technique for the management of Barrett esophagus (BE)-related neoplasia.
  • In this study, we sought to determine morphologic factors, which may influence EUS staging in 35 cases with intramucosal adenocarcinoma diagnosed by subsequent EMR, focusing on tumor characteristics and structural changes associated with BE.
  • The results illustrate how morphologic factors may affect EUS staging of superficial esophageal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagoscopy / methods. Mucous Membrane / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Esophagectomy. Esophagus / pathology. Esophagus / surgery. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047893.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, Nicolson M, Harper P, Seymour M, Hickish T: The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol; 2009 May;20(5):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
  • BACKGROUND: It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma].
  • This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy.
  • RESULTS: Of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n = 485), OGJ (n = 457) and gastric (n = 833) origins.
  • The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P = 0.68).
  • RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P = 0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis).
  • Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P = 0.85 and 0.62 compared with gastric).
  • CONCLUSIONS: In our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma.
  • Future RCTs should not exclude oesophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164454.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, Ten Kate FJ, Reitsma PH, van Kampen AH, Zwinderman AH, Baas F, van Lanschot JJ: Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol; 2008 Dec;15(12):3459-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus.
  • INTRODUCTION: The presence of lymphatic dissemination is an important predictor of survival in esophageal adenocarcinoma (EA).
  • Whole-genome oligonucleotide microarrays were used to evaluate the genetic signature of 77 esophageal cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825457.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


89. Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I: A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer; 2009 Jun 2;100(11):1725-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
  • Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma.
  • Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50 mg m(-2) day 1, cisplatin 60 mg m(-2) day 1, capecitabine 625 mg m(-2) b.i.d. daily) followed by surgery.
  • Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Epirubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 15;88(8):1788-95 [10760753.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):338-56 [11260097.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1223-9 [11953876.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):655-61 [11979246.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):199-204 [14760668.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):485-91 [9242759.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):497-8 [10088616.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1976-83 [15928658.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4483-9 [16002838.001]
  • [Cites] Radiology. 2005 Sep;236(3):841-51 [16118165.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Cancer. 2006 May 15;106(10):2119-27 [16607651.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD001556 [16855972.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Am J Surg. 2007 May;193(5):614-7; discussion 617 [17434367.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1673-9 [17660494.001]
  • [Cites] Contemp Clin Trials. 2008 Jan;29(1):32-41 [17544337.001]
  • [Cites] BMC Med. 2004 Sep 24;2:35 [15447788.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • (PMID = 19436301.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2695693
  •  go-up   go-down


90. Matono S, Fujita H, Sueyoshi S, Tanaka T, Yamana H, Shirouzu K: Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node. Jpn J Thorac Cardiovasc Surg; 2006 Jan;54(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
  • Here, we report a case of long-term survival after resection of an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
  • A 71-year-old woman was referred to our hospital with a tumor in the lower third of the thoracic esophagus, located just beneath the tracheal bifurcation because of an hiatal hernia.
  • The esophageal tumor and this lymph node were biopsied.
  • They were pathologically found to be an adenocarcinoma in the esophagus which had metastasised to the lymph node.
  • The pathological diagnosis was adenocarcinoma in Barrett's esophagus with the UICC stage classification of pT1, pN1, pM1-LYM, Stage IVB.
  • We recommend thoracoabdominal esophagectomy with three-field lymphadenectomy for an advanced carcinoma in the upper and middle thoracic esophagus regardless of histological types.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / complications. Esophageal Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 May;27(5):571-9 [12715226.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Dec;116(6):954-9 [9832686.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2002 Dec;8(6):328-35 [12517291.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Dig Surg. 2003;20(3):229-35; discussion 236-7 [12759503.001]
  • [Cites] World J Surg. 1994 Mar-Apr;18(2):266-72 [8042333.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] Surgery. 1995 Nov;118(5):845-55 [7482272.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16482930.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Lastraioli E, Taddei A, Messerini L, Comin CE, Festini M, Giannelli M, Tomezzoli A, Paglierani M, Mugnai G, De Manzoni G, Bechi P, Arcangeli A: hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J Cell Physiol; 2006 Nov;209(2):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus.
  • Alteration in ion channel function has been reported in different human pathologies, such as cardiac, neuromuscular, autoimmune diseases, and cancer.
  • We investigated the expression of hERG1 K+ channels in the human upper gastrointestinal tract, focusing our attention on the lower esophagus.
  • In particular, we analyzed by both Reverse transcription and polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) endoscopic samples obtained from normal subjects, from patients suffering from gastroesophageal reflux, associated or not with esophagitis, and from patients affected by Barrett's esophagus (BE), that is, intestinal metaplasia.
  • None of the normal samples, nor those from patients with gastro-esophageal reflux symptoms and reflux esophagitis expressed the hERG1 protein.
  • Data here reported, support the hypothesis that hERG1 expression marks an early step of the progression of normality to cancer in the human esophagus through a metaplastic and dysplastic stage.
  • [MeSH-major] Barrett Esophagus / pathology. Esophagus / metabolism. Ether-A-Go-Go Potassium Channels / genetics. Ether-A-Go-Go Potassium Channels / metabolism
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation. Humans. Male. Metaplasia. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16883575.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ether-A-Go-Go Potassium Channels; 0 / KCNH1 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


97. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM: Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer; 2007 May 7;96(9):1377-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
  • Our aim was to assess the immunohistochemical expression of hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, erythropoietin (Epo), Epo receptor (Epo-R), Glut-1 and vascular endothelial growth factor (VEGF) along with Ki67/MIB-1 in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
  • Endoscopic biopsies of normal squamous epithelium (NSE) (n=20), columnar-lined oesophagus (CLO) (n=15), CLO with intestinal metaplasia (n=20), dysplasia (n=17) and Barrett's type adenocarcinoma (n=20) were obtained.
  • Significant increases in the expression of HIF-2alpha (P=0.014), VEGF (P<0.0001), Epo-R (P<0.0001) and Ki67 (P<0.0001) were found as tissue progressed from NSE to adenocarcinoma.
  • HIF-2alpha was expressed late in the sequence and was only seen in dysplasia and adenocarcinoma.
  • High HIF-2alpha expression was seen in 12 out of 20 Barrett's type adenocarcinoma.
  • The late expression of HIF-2alpha in the Barrett's carcinogenesis sequence and its high expression in adenocarcinoma suggest that it is worth further investigation as a marker of disease progression and therapeutic target.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Basic Helix-Loop-Helix Transcription Factors / metabolism. Esophageal Neoplasms / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • [MeSH-minor] Biopsy. Disease Progression. Epithelial Cells / cytology. Epithelial Cells / pathology. Esophageal Diseases / pathology. Esophagus / cytology. Esophagus / pathology. Immunohistochemistry. Ki-67 Antigen / metabolism. Metaplasia. Receptors, Erythropoietin / metabolism. Reference Values. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2000 Feb;35(2):131-7 [10720109.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] J Pathol. 2000 Sep;192(1):14-8 [10951394.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1175-7 [11481392.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):261-6 [11556755.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2971-9 [12089227.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):969-81 [12209679.001]
  • [Cites] J Histochem Cytochem. 2003 Jan;51(1):129-32 [12502763.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53 [12579092.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1789-806 [12759237.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1021-9 [12807756.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):349-68, viii [12916665.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:7-30 [14531737.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):890-4 [14624783.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Neuroscientist. 2004 Apr;10(2):93-8 [15070483.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2376-86 [15160341.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8 [8445916.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):119-29 [8514029.001]
  • [Cites] Gut. 1995 Aug;37(2):168-73 [7557561.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):303-5 [9149888.001]
  • [Cites] BMJ. 1998 Apr 18;316(7139):1236-8 [9553006.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Dis Esophagus. 2004;17(4):322-7 [15569371.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i38-42 [15711007.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):823-30 [15743794.001]
  • [Cites] J Biomed Sci. 2005;12(1):229-41 [15864753.001]
  • [Cites] World J Gastroenterol. 2005 May 14;11(18):2697-703 [15884106.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):401-8 [16054089.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):135-45 [16161153.001]
  • [Cites] World J Gastroenterol. 2005 Nov 21;11(43):6807-14 [16425388.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):332-9 [16428469.001]
  • [Cites] Gut. 2006 Oct;55(10):1377-9 [16966694.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1029-38 [17021130.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1337-46 [17081104.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):95-103 [17179985.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):89-94 [10767821.001]
  • (PMID = 17437013.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Ki-67 Antigen; 0 / Receptors, Erythropoietin; 0 / Vascular Endothelial Growth Factor A; 0 / endothelial PAS domain-containing protein 1
  • [Other-IDs] NLM/ PMC2360174
  •  go-up   go-down


98. Chaves DM, Maluf Filho F, de Moura EG, Santos ME, Arrais LR, Kawaguti F, Sakai P: Endoscopic submucosal dissection for the treatment of early esophageal and gastric cancer--initial experience of a western center. Clinics (Sao Paulo); 2010 Apr;65(4):377-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection for the treatment of early esophageal and gastric cancer--initial experience of a western center.
  • OBJECTIVE: To evaluate the feasibility, early results and complications of the endoscopic submucosal dissection technique for treating early gastric and esophageal cancer at the Endoscopic Unit of Clinics Hospital and Cancer Institute of the São Paulo University.
  • MATERIALS AND METHODS: Twenty patients underwent endoscopic resection using the endoscopic submucosal dissection technique for early gastric or esophageal cancer.
  • RESULTS: Sixteen gastric adenocarcinoma lesions and six esophageal squamous carcinoma lesions were resected.
  • In the esophagus, all of the lesions were type IIb, with a mean diameter of 17.8 mm (6-30 mm).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Dissection / methods. Endoscopy / methods. Esophageal Neoplasms / surgery. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1998 Aug;59(5):502-8 [9705535.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):550-4; discussion 554-5 [9831855.001]
  • [Cites] Gastrointest Endosc. 1999 Oct;50(4):560-3 [10502182.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):776-82 [16650537.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Can J Gastroenterol. 2009 May;23(5):357-63 [19440567.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):24-9 [17252456.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):36-40 [17252458.001]
  • [Cites] Gastric Cancer. 2007;10(1):1-11 [17334711.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):799-804 [18158151.001]
  • [Cites] Gastric Cancer. 2006;9(4):262-70 [17235627.001]
  • (PMID = 20454494.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2862673
  • [Keywords] NOTNLM ; Endoscopic mucosal / early esophageal cancer / early gastric cancer / endoscopic submucosal dissection / endoscopy / resection
  •  go-up   go-down


99. Shaheen NJ, Peery AF, Overholt BF, Lightdale CJ, Chak A, Wang KK, Hawes RH, Fleischer DE, Goldblum JR, AIM Dysplasia Investigators: Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc; 2010 Sep;72(3):490-496.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus.
  • BACKGROUND: After endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Catheter Ablation / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagoscopy. Postoperative Complications / pathology. Postoperative Complications / surgery. Precancerous Conditions / pathology. Precancerous Conditions / surgery
  • [MeSH-minor] Aged. Biopsy. Disease Progression. Esophagus / pathology. Female. Follow-Up Studies. Humans. Male. Metaplasia. Middle Aged. Predictive Value of Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):239-45 [9500226.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Endoscopy. 2008 May;40(5):380-7 [18459074.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):867-76 [18561930.001]
  • [Cites] Endoscopy. 2008 Dec;40(12):1008-15 [19065484.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1366-73 [19491850.001]
  • (PMID = 20598302.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00282672
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007634-15; United States / NIDDK NIH HHS / DK / T32 DK 07634; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / IH P30 DK034987; United States / NIDDK NIH HHS / DK / T32 DK007634
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS289916; NLM/ PMC3093936
  • [Investigator] Shaheen NJ; Madanick RD; Galanko JA; Sharma P; Overholt BF; Wolfsen HC; Sampliner RE; Wang KK; Falk GW; Bronner MP; Goldblum JR; Bennett AE; Jobe BA; Eisen GM; Fennerty MB; Hunter JG; Fleischer DE; Sharma VK; Hawes RH; Hoffman BJ; Rothstein RI; Gordon SR; Mashimo H; Chang KJ; Muthusamy VR; Edmundowicz SA; Spechler SJ; Siddiqui AA; Souza RF; Infantolino A; Kimmey MB; Chak A; Lightdale CJ
  •  go-up   go-down


100. Bahmanyar S, Ye W: Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer; 2006;54(2):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden.
  • We conducted a large population-based case-control study in Sweden to examine the association of dietary patterns and the development of cancers from the esophagus or gastroesophageal junction.
  • In total 185 patients with esophageal adenocarcinoma, 165 with esophageal squamous-cell carcinoma, 258 with gastric cardia adenocarcinoma, and 815 randomly selected population controls underwent face-to-face interviews.
  • A high score of Western diet was associated with increased risks of gastric cardia adenocarcinoma (high 3rd tertile vs. low 1st quartile, OR = 1.8, 95% CI = 1.1-2.9, P for trend = 0.04) and esophageal adenocarcinoma (high 3rd tertile vs. low 1st tertile, OR = 1.6, 95% CI = 0.9-3.1, P for trend = 0.13), whereas a dietary pattern characterized by high beer and liquor intake (alcohol drinker) significantly increased the risk of squamous-cell carcinoma of the esophagus (3rd tertile vs. low 1st tertile, OR = 3.5, 95% CI = 1.9-6.3, P for trend < 0.0001).
  • Our study confirms the important role of diet in the carcinogenesis of esophageal and cardia cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Food Habits. Stomach Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898861.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA57947-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement